<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680114</article-id><article-id pub-id-type="doi">10.3390/vaccines12121361</article-id><article-id pub-id-type="publisher-id">vaccines-12-01361</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0374-3841</contrib-id><name><surname>Hendrix</surname><given-names>Emily K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01361" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-7638-9067</contrib-id><name><surname>Sha</surname><given-names>Jian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01361" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01361" ref-type="aff">2</xref><xref rid="c1-vaccines-12-01361" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Kilgore</surname><given-names>Paul B.</given-names></name><xref rid="af1-vaccines-12-01361" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Neil</surname><given-names>Blake H.</given-names></name><xref rid="af1-vaccines-12-01361" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Verma</surname><given-names>Atul K.</given-names></name><xref rid="af1-vaccines-12-01361" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5223-3012</contrib-id><name><surname>Chopra</surname><given-names>Ashok K.</given-names></name><xref rid="af1-vaccines-12-01361" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01361" ref-type="aff">2</xref><xref rid="af3-vaccines-12-01361" ref-type="aff">3</xref><xref rid="af4-vaccines-12-01361" ref-type="aff">4</xref><xref rid="af5-vaccines-12-01361" ref-type="aff">5</xref><xref rid="c1-vaccines-12-01361" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Meurens</surname><given-names>Fran&#x000e7;ois</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01361"><label>1</label>Department of Microbiology &#x00026; Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; <email>ekhendri@utmb.edu</email> (E.K.H.); </aff><aff id="af2-vaccines-12-01361"><label>2</label>Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA</aff><aff id="af3-vaccines-12-01361"><label>3</label>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA</aff><aff id="af4-vaccines-12-01361"><label>4</label>Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA</aff><aff id="af5-vaccines-12-01361"><label>5</label>Center for Biodefense and Emerging Infectious Diseases, Galveston, TX 77555, USA</aff><author-notes><corresp id="c1-vaccines-12-01361"><label>*</label>Correspondence: <email>jisha@utmb.edu</email> (J.S.); <email>achopra@utmb.edu</email> (A.K.C.); Tel.: +1-(409)-747-0578 (A.K.C.)</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1361</elocation-id><history><date date-type="received"><day>08</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>28</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Plague, caused by <italic toggle="yes">Yersinia pestis</italic>, poses a public health threat not only due to sporadic outbreaks across the globe but also due to its potential as a biothreat agent. Ironically, among the seven deadliest pandemics in global history, three were caused by <italic toggle="yes">Y. pestis</italic>. Pneumonic plague, the more contagious and severe form of the disease, is difficult to contain, requiring either prophylactic antibiotic treatment or vaccination. However, no vaccine (live attenuated or subunit) is currently approved by the Food and Drug Administration, requiring rigorous preclinical studies in different animal models, thus forming the basis of this study. <bold>Objectives</bold>: The aim of this study was to evaluate the efficacy and immune responses of two live attenuated vaccines (LAVs), LMA and LMP, either alone or in combination with a trivalent adenoviral vector-based vaccine (Ad5-YFV), in IL-17A-depleted and IgG control mice by using an anti-IL-17A monoclonal antibody (mAb) or its matched isotype IgG, respectively. <bold>Methods</bold>: IL-17A mAb or IgG isotype control was administered to mice twice per week to their respective groups during the course of immunization. Serum, spleens, and broncho-alveolar lavage fluid (BALF) were collected for assessing immunological responses, and another cohort of mice was intranasally challenged with a lethal dose of parental <italic toggle="yes">Y. pestis</italic> CO92. <bold>Results</bold>: Robust humoral and cellular immune responses followed by complete protection were observed in all vaccinated animals against highly lethal intranasal challenge doses of parental <italic toggle="yes">Y. pestis</italic> CO92. Serum IgG titers to YscF and overall mucosal IgA titers to all three antigens of the Ad5-YFV vaccine were significantly lower, with slightly reduced serum LcrV-neutralizing antibodies when IL-17A was depleted compared to IgG control animals during the course of immunization. A remarkable reduction in Th1 (IFN&#x003b3; or IL-2) and Th17 cell populations was observed in IL-17A-depleted mice compared to IgG controls in response to vaccination. On the other hand, B cell activities in germinal centers, overall activated antigen-specific T cells, and memory B and T cells remained at comparable levels in both vaccinated IL-17A-depleted and IgG control mice. <bold>Conclusions</bold>: These data demonstrated the effectiveness of our vaccines even under the reduced levels of both Th1 and Th17 responses and thus should be suitable for those individuals associated with certain immune deficiencies.</p></abstract><kwd-group><kwd><italic toggle="yes">Y. pestis</italic></kwd><kwd>live attenuated and adenovirus-based plague vaccines</kwd><kwd>homologous and heterologous vaccinations</kwd><kwd>IL-17A-depleted mice</kwd><kwd>flow cytometry</kwd><kwd>immunogenicity</kwd><kwd>pneumonic plague</kwd></kwd-group><funding-group><award-group><funding-source>Biodefense T32 Training Fellowship</funding-source><award-id>T32-AI060549</award-id></award-group><award-group><funding-source>Jeane B. Kempner fellowship</funding-source></award-group><award-group><funding-source>Antimicrobial Resistance Training Program at the Texas Medical Center</funding-source><award-id>T32-AI179595</award-id></award-group><award-group><funding-source>NIH</funding-source><award-id>R01 AI153524</award-id></award-group><award-group><funding-source>UTMB Technology Commercialization Program</funding-source></award-group><award-group><funding-source>John S. Dunn Endowment funding</funding-source></award-group><funding-statement>E.K.H. was supported in part by the Biodefense T32 Training Fellowship (T32-AI060549) awarded to A.K.C. and by the Jeane B. Kempner fellowship. P.B.K. was supported in part by the Antimicrobial Resistance Training Program at the Texas Medical Center (T32-AI179595). These studies were supported by funding from an NIH (R01 AI153524) grant as well as the UTMB Technology Commercialization Program and John S. Dunn Endowment funding awarded to AKC.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01361"><title>1. Introduction</title><p>Plague, the disease caused by <italic toggle="yes">Yersinia pestis</italic>, has resulted in three pandemics with a staggering number of deaths exceeding 200 million [<xref rid="B1-vaccines-12-01361" ref-type="bibr">1</xref>]. Plague continues to re-emerge, especially in regions of endemicity. A 2017&#x02013;2018 plague epidemic in Madagascar resulted in more than 2500 cases and over 200 deaths [<xref rid="B2-vaccines-12-01361" ref-type="bibr">2</xref>]. Significantly, the majority of cases in this epidemic were pneumonic rather than the more common bubonic manifestation [<xref rid="B2-vaccines-12-01361" ref-type="bibr">2</xref>]. Pneumonic plague is typically much more severe and has a much higher fatality rate than bubonic plague, approaching 100% if left untreated [<xref rid="B2-vaccines-12-01361" ref-type="bibr">2</xref>]. In addition, antibiotic-resistant strains of <italic toggle="yes">Y. pestis</italic> have emerged [<xref rid="B3-vaccines-12-01361" ref-type="bibr">3</xref>], making treatment strategies difficult. Therefore, vaccination remains the most effective approach in preventing plague transmission. There are, however, no Food and Drug Administration (FDA)-approved plague vaccines [<xref rid="B4-vaccines-12-01361" ref-type="bibr">4</xref>]. </p><p>Earlier plague vaccines were either heat- or formaldehyde-inactivated <italic toggle="yes">Y. pestis</italic> bacilli. The use of these vaccines was discontinued largely due to severe side effects and limited efficacy against pneumonic plague [<xref rid="B2-vaccines-12-01361" ref-type="bibr">2</xref>]. Subsequently, live attenuated [<xref rid="B5-vaccines-12-01361" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-12-01361" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01361" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01361" ref-type="bibr">8</xref>], vector-based (bacterial or viral) [<xref rid="B9-vaccines-12-01361" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01361" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01361" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01361" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-12-01361" ref-type="bibr">13</xref>], recombinant [<xref rid="B14-vaccines-12-01361" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01361" ref-type="bibr">15</xref>], DNA [<xref rid="B16-vaccines-12-01361" ref-type="bibr">16</xref>], or the most recent messenger RNA (mRNA)-based [<xref rid="B17-vaccines-12-01361" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01361" ref-type="bibr">18</xref>] strategies have been employed for plague vaccine development. The advantages and disadvantages of these vaccines have been detailed by us and other researchers in several review articles [<xref rid="B2-vaccines-12-01361" ref-type="bibr">2</xref>,<xref rid="B19-vaccines-12-01361" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01361" ref-type="bibr">20</xref>].</p><p>A vast majority of subunit and vector-based plague vaccines in preclinical and clinical development are based on a combination of the fraction 1 capsule-like antigen (F1) and the low-calcium-response V antigen (LcrV) on the needle tip of the type 3 secretion system (T3SS) [<xref rid="B2-vaccines-12-01361" ref-type="bibr">2</xref>,<xref rid="B21-vaccines-12-01361" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-01361" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01361" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01361" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01361" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01361" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01361" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01361" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01361" ref-type="bibr">29</xref>]. However, <italic toggle="yes">Y. pestis</italic> strains that lack the F1 capsule (F1<sup>-</sup>) and remain virulent have been reported, and LcrV alone does not provide adequate protection against infection [<xref rid="B9-vaccines-12-01361" ref-type="bibr">9</xref>,<xref rid="B30-vaccines-12-01361" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01361" ref-type="bibr">31</xref>]. We have generated multiple vaccine candidates, two live attenuated vaccines (LAVs) and one adenovirus-based vaccine, that have been characterized in detail, overcoming some drawbacks encountered with other vaccine candidates. The LAVs are triple-deletion mutants of <italic toggle="yes">Y. pestis</italic> strain CO92 deleted for genes encoding Braun lipoprotein (Lpp), acetyltransferase B (MsbB), and attachment-invasion locus (Ail), designated as LMA, or deletion of Lpp, MsbB, and plasminogen-activating protease (Pla), designated as LMP. Both LMA and LMP were avirulent while remaining highly immunogenic in mouse and rat models [<xref rid="B7-vaccines-12-01361" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01361" ref-type="bibr">8</xref>,<xref rid="B32-vaccines-12-01361" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-12-01361" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01361" ref-type="bibr">34</xref>] and are classified as exempt strains by the Centers for Disease Control and Prevention (CDC) (<uri xlink:href="https://www.selectagents.gov/sat/exclusions/hhs.htm">https://www.selectagents.gov/sat/exclusions/hhs.htm</uri>; accessed 29 November 2023) and the National Institutes of Health (NIH). Hence, these can now be used at the lower biosafety level BSL-2/ABSL-2. The adenovirus-based vaccine, Ad5-YFV, is based on a replication-defective human adenovirus type 5 (Ad5) encompassing a fusion gene cassette for three prominent plague antigens: the <italic toggle="yes">Yersinia</italic> secretion protein F (YscF) of the T3SS barrel, F1, and LcrV [<xref rid="B10-vaccines-12-01361" ref-type="bibr">10</xref>,<xref rid="B35-vaccines-12-01361" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-12-01361" ref-type="bibr">36</xref>]. Incorporating YscF into this vaccine platform compensates for the lack of protection seen with the Ad5-LcrV monovalent vaccine or other F1V vaccine candidates against <italic toggle="yes">Y. pestis</italic> strains lacking the F1 capsule [<xref rid="B9-vaccines-12-01361" ref-type="bibr">9</xref>]. </p><p>The implication of the IL-17 pathway in an acute pneumonic plague mouse model was first shown in 2007, when elevated production of IL-17A and its promoting cytokines, such as transforming growth factors beta (TGF-&#x003b2;), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-&#x003b1;), and IL-1&#x003b2;, were observed in inflamed lungs [<xref rid="B37-vaccines-12-01361" ref-type="bibr">37</xref>]. Subsequently, IL-17A produced from innate immune cells, especially neutrophils, was shown to have a protective role against pneumonic infection in mice through orchestrating interferon gamma (IFN&#x003b3;)-activated macrophage programming [<xref rid="B38-vaccines-12-01361" ref-type="bibr">38</xref>]. Furthermore, vaccinating B cell-deficient mice with D27-pLpxL, a live attenuated <italic toggle="yes">Y. pestis</italic> strain, induced cell-mediated protection against lethal pulmonary <italic toggle="yes">Y. pestis</italic> infection, and prime-boost immunization conferred better protection than prime-only vaccination of mice [<xref rid="B39-vaccines-12-01361" ref-type="bibr">39</xref>]. Importantly, this improved survival did not result from enhanced bacterial clearance but was associated with increased levels of IL-17A mRNA and protein in the lungs of challenged mice. These data suggested that an optimal plague vaccine should also be able to elicit a Th17 response in addition to a Th1 response [<xref rid="B39-vaccines-12-01361" ref-type="bibr">39</xref>]. Consistent with this, vaccinating mice and rats with our two LAVs, either alone or in combination with Ad5-YFV, also induced significantly higher levels of both Th1 and Th17 responses during our previous studies [<xref rid="B8-vaccines-12-01361" ref-type="bibr">8</xref>,<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>]. To further assess the role of IL-17A on the efficiency of our vaccines, we evaluated both humoral and cellular immunity in IL-17A-depleted mice. Complete protection was observed in all immunized mice against lethal pulmonary <italic toggle="yes">Y. pestis</italic> challenge, irrespective of whether IL-17A was depleted or not. Of note, IL-17A influenced the production of both humoral and cellular immunity. To our knowledge, this is the first detailed immunogenicity and challenge study of plague vaccines in IL-17A-depleted mice. </p></sec><sec id="sec2-vaccines-12-01361"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-12-01361"><title>2.1. Animals</title><p>Six-week-old female Swiss Webster mice were purchased from Jackson Laboratory (Bar Harbor, ME). All studies were ethically performed under an approved Institutional Animal Care and Use Committee (IACUC) protocol (Office of Laboratory Animal Welfare assurance number A3314-01).</p></sec><sec id="sec2dot2-vaccines-12-01361"><title>2.2. In Vivo Treatment with Antibodies</title><p>For IL-17A depletion, mice were injected intraperitoneally (i.p.) in the lower right quadrant with anti-IL-17A monoclonal antibody (mAb; 150 &#x000b5;g/mouse/treatment; BioXCell, Lebanon, NH, USA; Clone 17F3) twice per week over the duration of vaccination before harvesting splenocytes and challenge. The corresponding isotype control antibodies were similarly used (Mouse IgG1; BioXCell; Clone MOPC-21). The concentrations of mAbs used were based on the manufacturer&#x02019;s instructions.</p></sec><sec id="sec2dot3-vaccines-12-01361"><title>2.3. Bacterial Strains and Vaccines</title><p>The human <italic toggle="yes">Y. pestis</italic> isolate CO92 was obtained from BEI Resources (Manassas, VA, USA). The live attenuated vaccine candidates LMA and LMP are triple-deletion mutants (&#x00394;<italic toggle="yes">lpp</italic>&#x00394;<italic toggle="yes">msb</italic>B&#x00394;<italic toggle="yes">ail</italic> [LMA] and &#x00394;<italic toggle="yes">lpp</italic>&#x00394;<italic toggle="yes">msbB</italic>&#x00394;<italic toggle="yes">pla</italic> [LMP]) of CO92, deleted for genes encoding Braun lipoprotein (Lpp), acetyltransferase B (MsbB), and attachment-invasion locus (Ail) or plasminogen-activating protease (Pla), respectively [<xref rid="B8-vaccines-12-01361" ref-type="bibr">8</xref>,<xref rid="B32-vaccines-12-01361" ref-type="bibr">32</xref>]. As we previously described [<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>], LMA and LMP were prepared by inoculating heart infusion broth (HIB) in an overnight shaking culture (28 &#x000b0;C, 180 rpm). The LAVs were then aliquoted into 500 &#x000b5;L volumes at 1 &#x000d7; 10<sup>9</sup> CFU/mL with 25% glycerol and stored at &#x02212;80 &#x000b0;C. For vaccination, the stored LAVs were further diluted to the desired concentration in PBS. The replication-deficient human adenoviral type 5 vector-based vaccine Ad5-YFV includes genes for three plague antigens: YscF (TS barrel), F1 (capsule), and LcrV (T3SS needle) [<xref rid="B10-vaccines-12-01361" ref-type="bibr">10</xref>]. The Ad5-YFV vaccine was purified at the Baylor College of Medicine Vector Development Laboratory and at Lonza (Houston, TX) under GLP conditions. Ad5-YFV was aliquoted at 1 &#x000d7; 10<sup>12</sup> v.p./mL and stored at &#x02212;80 &#x000b0;C. Titration was routinely confirmed before and after each inoculation. All studies utilizing <italic toggle="yes">Y. pestis</italic> were performed in Tier 1 select agent BSL-3 laboratories at UTMB in the GNL-Keiller complex in Galveston, Texas. All animal studies were conducted in ABSL-3 facilities of the GNL-Keiller complex.</p></sec><sec id="sec2dot4-vaccines-12-01361"><title>2.4. Vaccination and Challenge Studies</title><p>During IL-17A depletion, mice were anesthetized by 2&#x02013;4% isoflurane inhalation and a 2 L/min O<sub>2</sub> flow rate in an induction chamber (VetEquip, Pleasanton, CA, USA) and immunized with two doses of LMA or LMP alone intramuscularly (i.m., 2 &#x000d7; 10<sup>6</sup> CFU/50 &#x000b5;L) in the hind limb, or in combination with Ad5-YFV intranasally (i.n., 5.5 &#x000d7; 10<sup>10</sup> PFU/50 &#x000b5;L). Vaccines were administered 21 days apart. PBS was administered to animals as unvaccinated controls.</p><p>Mice (<italic toggle="yes">n =</italic> 10 per group per IL-17A or IgG mAb treatment) were anesthetized by isoflurane inhalation and retro-orbitally bled. Serum samples were pooled prior to vaccination or challenge and around 20 days after each immunization. On day 39, a cohort with 5 mice from each group was anesthetized by isoflurane inhalation and challenged i.n. with 100 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92. Seven days post-initial challenge, surviving mice and na&#x000ef;ve age-matched control mice were re-challenged i.n. with 10,000 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92. On day 49, animals were humanely euthanized using i.p. injection of 5&#x02013;10 mg/kg ketamine and xylazine in 100 &#x000b5;L followed by cervical dislocation. Spleens and broncho-alveolar lavage fluid (BALF) were collected individually from a separate cohort with the remaining 5 mice in each group for immunological analysis.</p></sec><sec id="sec2dot5-vaccines-12-01361"><title>2.5. Antibody Titers </title><p>Antibody titers were determined via ELISA as we previously described [<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>]. Briefly, MaxiSorp Nunc ELISA plates (Fisher Scientific, Newington, NH, USA) were coated with 100 ng/100 &#x000b5;L of recombinant fusion protein (rF1V, BEI Resources, Manassas, VA, USA) or individual antigens (rF1, rLcrV, or rYscF) in carbonate buffer and incubated overnight at 4&#x000b0;C. Plates were washed with Dulbecco&#x02019;s PBS (DPBS) containing 0.05% Tween 20 and then blocked with 1% bovine serum albumin (BSA) (Sigma Aldrich, St. Louis, MO, USA). Serum and BALF were 2-fold serially diluted and added to plates for 1 h at room temperature. Plates were then washed and horseradish peroxidase (HRP)-conjugated secondary anti-mouse antibodies for IgG, IgG1, IgG2c, or IgA (Southern Biotech, Birmingham, AL, USA) diluted to 1:8000 were added. Plates were washed and 3,3&#x02019;,5,5&#x02019;-tetramethyl-benzidine (TMB) substrate was added. The reaction was stopped using 2N H<sub>2</sub>SO<sub>4</sub>, and absorbance was measured at 450 nm using a VersaMax tunable microplate reader (Molecular Devices, San Jose, CA, USA). Total IgG, IgG1, IgG2c, and IgA were measured in triplicate. </p></sec><sec id="sec2dot6-vaccines-12-01361"><title>2.6. Neutralization Antibody Analysis</title><p>LcrV Mab7.3 was biotinylated using EZ-Link&#x02122; Sulfo-NHS Biotin (ThermoFisher, Waltham, MA, USA) [<xref rid="B41-vaccines-12-01361" ref-type="bibr">41</xref>] and purified with Sephadex G-25 resin PD-10 desalting columns (Cytiva, Marlborough, MA, USA) following the manufacturer&#x02019;s instructions. The biotinylated antibody was eluted in PBS, and its concentration was determined using a Nanodrop&#x02122; One Spectrophotometer (Invitrogen, Carlsbad, CA, USA) at A280. Neutralization antibodies were measured using competitive ELISA [<xref rid="B42-vaccines-12-01361" ref-type="bibr">42</xref>] and completed as follows: Maxisorp Nunc ELISA plates were coated with 200 ng of recombinant LcrV (rV) (BEI) in 100 &#x003bc;L of PBS overnight at 4 &#x000b0;C. Unbound antigens were removed by three washes with Dulbecco&#x02019;s PBS (DPBS) containing 0.05% Tween 20. Plates were blocked with 150 &#x000b5;l of 2% skim milk powder (Millipore Sigma, Burlington, MA, USA) in PBS for 1 h at room temperature. After washing, wells were incubated for 2 h with 80 ng/well of biotinylated LcrV Mab7.3 in 100 &#x003bc;L of blocking buffer. After washing, heterologously vaccinated IL-17A-depleted mouse serum was diluted 1:10 and then 2-fold serially diluted and incubated for 2 h at room temperature. After washing, 100 &#x003bc;L of 1:10,000 streptavidin-HRP conjugate was added for 45 min and developed in 100 &#x003bc;L of TMB. Development of the colorimetric reaction was stopped using 2N H<sub>2</sub>SO<sub>4</sub> and absorbance was measured at 450 nm using a VersaMax tunable microplate reader. The dilution of the test serum that inhibited binding of the biotinylated Mab7.3 to rV by 50% or greater (NT<sub>50</sub>) represented the level of neutralizing antibodies.</p></sec><sec id="sec2dot7-vaccines-12-01361"><title>2.7. Flow Cytometry Analysis</title><p>T cell phenotypes: Spleens were collected and processed as previously described [<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>]. After 2 days of stimulation with 100 &#x000b5;g/mL of rF1V antigen (BEI Resources), 1X Brefeldin A was added for an additional 4 h. Splenocytes were then harvested, blocked with anti-mouse CD16/32 antibodies (Biolegend, San Diego, CA, USA), and stained with fixable viability dye eFluor 780 (Invitrogen), Alexa Fluor 700 anti-mouse CD3 (Biolegend), Brilliant Violet 785 anti-mouse CD4 (Biolegend), FITC anti-mouse CD8 (Biolegend), Brilliant Violet 510 anti-mouse CD44 (Biolegend), Brilliant Violet 711 anti-mouse CD62-L (Biolegend), PE anti-mouse CD127 (Biolegend), Brilliant Violet 605 anti-mouse CD25 (Biolegend), and APC anti-mouse CD134 (Biolegend). Cells were permeabilized for intracellular staining with the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA, USA) at 4 &#x000b0;C overnight and then stained with Brilliant Ultra Violet anti-mouse CD69 (BD Biosciences, San Jose, CA, USA), PE/Cyanine7 anti-mouse IL-17A (Biolegend), PerCP/Cyanine5.5 anti-mouse IFN&#x003b3; (Biolegend), eFluor 450 anti-mouse TNF&#x003b1; (eBioscience), PE-CF594 anti-mouse IL-2 (BD Biosciences), and Brilliant Violet 650 anti-mouse IL-4 (BD Biosciences) and analyzed via flow cytometry as described in our previous studies [<xref rid="B7-vaccines-12-01361" ref-type="bibr">7</xref>,<xref rid="B9-vaccines-12-01361" ref-type="bibr">9</xref>,<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>] on the BD FACSymphony A5.</p><p>B cell phenotypes: Splenocytes isolated from the above mice were directly subjected to B cell panel staining without rF1V stimulation. Briefly, splenocytes (2 &#x000d7; 10<sup>6</sup> cells) were blocked with anti-mouse CD16/32 (Biolegend) antibodies followed by staining with fixable viability dye eFluor 780 (Invitrogen), FITC anti-mouse CD19 (Biolegend), Alexa Fluor 700 anti-mouse CD3 (Biolegend), Brilliant Violet 650 anti-mouse CD138 (BD Biosciences), PE-Cy7 anti-mouse CD38 (Biolegend), PerCP/Cyanine 5.5 anti-mouse GL7 (Biolegend), Brilliant Violet 510 anti-mouse IgD (Biolegend), Brilliant Violet 421 anti-mouse CD80 (Biolegend), Brilliant Violet 605 anti-mouse CD73 (Biolegend), and PE anti-mouse PDL2 (Biolegend), and analyzed via flow cytometry on the BD FACSymphony A5. Flow cytometry data were prepared via FlowJo software v10.10.</p></sec><sec id="sec2dot8-vaccines-12-01361"><title>2.8. Statistical Analysis</title><p>All outcomes were statistically compared using appropriate parametric and non-parametric tests such as Kaplan&#x02013;Meier with Mantel&#x02013;Cox tests for survival. <italic toggle="yes">In vitro</italic> experiments were performed in triplicate. Statistical analysis between groups was conducted using one- and two-way analysis of variance (ANOVAs). Results were plotted in GraphPad PRISM 9 software, with results expressed as means &#x000b1; standard deviation (SD). <italic toggle="yes">p</italic>-values &#x0003c; 0.05 were considered significant.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01361"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01361"><title>3.1. Vaccinated Animals Are Protected Against Pneumonic Plague</title><p>To deplete IL-17A, anti-IL-17A monoclonal antibodies (mAbs) were administered to mice twice per week by the intraperitoneal (i.p.) route during the entire course of immunization, and isotype control IgG was injected into control animals. Both IL-17A-depleted and IgG control mice were vaccinated either intramuscularly (i.m.) with LMA or LMP individually (homologous strategy) or in combination with intranasal (i.n.) delivery of Ad5-YFV (heterologous strategy). Vaccines were administered in a prime-boost regimen 21 days apart, with prime-pull vaccinations being those where Ad5-YFV was administered as the second dose in a heterologous strategy (<xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A). During the depletion and immunization course, we did not observe any local or systemic adverse effects, such as weight loss, ruffled fur, or injection site redness in either IL-17A-depleted or IgG control mice. Roughly 3 weeks post-boost vaccination, mice were i.n. challenged first with 100 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92, where 1 LD<sub>50</sub> is 500 colony-forming units (CFU) of CO92 in Swiss Webster mice [<xref rid="B30-vaccines-12-01361" ref-type="bibr">30</xref>,<xref rid="B43-vaccines-12-01361" ref-type="bibr">43</xref>]. All vaccination strategies, regardless of the order or combination, provided 100% protection to immunized mice, irrespective of the status of IL-17A depletion, while 100% lethality was observed in unvaccinated control mice (given phosphate-buffered saline [PBS] as a vehicle) 3 days post-infection (d.p.i.) (<xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>B,C). Seven days post-initial challenge, surviving vaccinated mice and new age-matched na&#x000ef;ve control animals were re-challenged i.n with 10,000 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92 and observed over 21 days. All vaccination strategies provided 100% protection to mice, while 100% lethality was observed in challenge control mice 2 d.p.i. (<xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>D,E). Secondary challenge at an extremely high dose of <italic toggle="yes">Y. pestis</italic> in vaccinated mice not only mimics the accumulation of <italic toggle="yes">Y. pestis</italic> bacilli in the environment during plague outbreaks but also showcases the efficacy of the recall immune response in immunized animals, which usually reaches its peak around 7&#x02013;10 days post-challenge. Vaccinated mice exhibited no significant clinical signs, such as weight loss, ruffled fur, or conjunctivitis, post-challenge compared to unimmunized animals.</p></sec><sec id="sec3dot2-vaccines-12-01361"><title>3.2. Vaccinated Mice Exhibit Increased Antibody and B Cell Responses</title><p>Serum was collected prior to challenge with <italic toggle="yes">Y. pestis</italic> CO92, around day 20 (prime) and 16 days post-boost immunization (day 37 of the study) (<xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A). Both IL-17A-depleted and IgG control mice elicited significantly increased IgG titers to the recombinant F1 and LcrV fusion protein (rF1V) compared to unvaccinated control animals, irrespective of the vaccination combination (<xref rid="vaccines-12-01361-f002" ref-type="fig">Figure 2</xref>A). F1V IgG titers increased by up to 1 log from the prime to boost vaccination. Compared to IgG control mice, significantly higher F1V IgG titers were noted in IL-17A-depleted mice, except for LMP&#x02013;Ad5-YFV vaccinated animals, in which a comparable level of F1V IgG was observed. On the other hand, slightly lower F1V IgG titers were noted in homologously vaccinated mice compared to heterologously vaccinated animals in both IL-17A-depleted and IgG control mice, suggesting that the heterologous strategy of vaccination produced improved humoral responses compared to the homologous strategy (<xref rid="vaccines-12-01361-f002" ref-type="fig">Figure 2</xref>A). We next examined IgG antibody isotypes, IgG1 and IgG2a, in the serum of vaccinated mice to evaluate the T helper 1 (Th1) versus Th2 bias. Vaccinated mice generally showed an overall balanced F1V-specific Th1 vs. Th2 response; however, animals that received LAVs as the first dose, irrespective of IL-17A depletion status, were slightly skewed to a Th2 response with higher IgG1 over IgG2a. In contrast, animals vaccinated first with Ad5-YFV had either equal levels of IgG1 and IgG2a (in IgG control mice) or slightly higher IgG2a (in IL-17A-depleted mice), representing a more balanced or Th1 response (<xref rid="vaccines-12-01361-f002" ref-type="fig">Figure 2</xref>B,C). These data suggested that the types of Th responses developed were likely associated with the types of vaccines and the influence of IL-17A on antibody isotype class switching appeared minimal.</p><p>To further analyze the humoral response in vaccinated mice, IgG titers in boost sera (day 37) to three individual plague-specific antigens F1, LcrV, and YscF, constituents of the Ad5-YFV vaccine, were assessed. Overall, all vaccinated mice, irrespective of IL-17A depletion status, demonstrated significantly higher anti-F1, -LcrV, and -YscF serum IgG titers compared to unvaccinated control mice (<xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>A&#x02013;C). Antibody titers were highest to F1, indicating its dominance in the serum and reflecting antibody titers to the F1V fusion antigen. The F1 IgG titers were significantly higher in IL-17A-depleted mice than in IgG control animals (<xref rid="vaccines-12-01361-f002" ref-type="fig">Figure 2</xref>A and <xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>A). In contrast, vaccinated IL-17A-depleted mice developed significantly lower YscF-specific IgG titers compared to vaccinated IgG controls (<xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>C). The influence of IL-17A on the production of LcrV antibodies varied and seemed dependent on the vaccines that mice received. More specifically, compared to immunized IL-17A-depleted mice, higher anti-LcrV titers were observed in IgG control mice vaccinated with either LMA-LMA or Ad5-YFV&#x02013;LMP. On the other hand, a lower anti-LcrV titer was noted when IgG control mice were immunized with LMP-LMP (<xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>B). </p><p>To gauge the level of neutralizing antibodies in the serum of vaccinated mice, competitive ELISAs were performed, whereby biotinylated LcrV Mab7.3, shown to passively protect mice against both bubonic and pneumonic plague [<xref rid="B44-vaccines-12-01361" ref-type="bibr">44</xref>], was used. As depicted in <xref rid="vaccines-12-01361-f004" ref-type="fig">Figure 4</xref>A,B, heterologous vaccination strategies resulted in the generation of serum antibodies capable of competitively binding to the rV epitope specific for LcrV Mab7.3. These antibody titers were slightly higher when the Ad5-YFV vaccine was administered first. Fifty percent of biotinylated LcrV Mab7.3 was outcompeted roughly at a serum dilution of 1:240 when Ad5-YFV was administered first, compared to roughly 1:120 when LAVs were administered first (<xref rid="vaccines-12-01361-f004" ref-type="fig">Figure 4</xref>C,D). Subsequently, we compared the ability of serum at a dilution of 1:80 to outcompete biotinylated LcrV Mab7.3 between IL-17A-depleted and IgG control mice. As noted in <xref rid="vaccines-12-01361-f004" ref-type="fig">Figure 4</xref>, the ability of serum antibodies to competitively bind was slightly lower when IL-17A was depleted in vaccinated mice (striped blue bar), compared to vaccinated IgG control animals (solid blue bar).</p><p>To evaluate mucosal immunity, we examined IgA antibody titers in broncho-alveolar lavage fluid (BALF). Overall, immunized mice developed higher IgA titers than unvaccinated animals (<xref rid="vaccines-12-01361-f005" ref-type="fig">Figure 5</xref>A&#x02013;D). Importantly, IgA antibody titers to all examined antigens in vaccinated IL-17A-depleted mice were either significantly lower or at similar levels compared to immunized IgG control animals (<xref rid="vaccines-12-01361-f005" ref-type="fig">Figure 5</xref>A&#x02013;D). This indicated that IL-17A influenced mucosal antibody production as opposed to serum IgG titers, where the influence of IL-17A was most likely dependent on the antigens themselves (<xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>A&#x02013;C). Importantly, irrespective of IL-17A depletion status, the highest IgA titers were observed in prime-pull immunized animals, followed by mice receiving other heterologous vaccinations. Mice receiving LAVs had the lowest IgA titers in BALF (<xref rid="vaccines-12-01361-f005" ref-type="fig">Figure 5</xref>A&#x02013;D).</p><p>To further examine humoral immune responses, splenocytes were isolated from vaccinated IL-17A-depleted, IgG control, and unvaccinated control animals (<xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A). Cells were stained for germinal center activity (CD3<sup>-</sup>CD138<sup>-</sup>CD19<sup>+</sup>CD38<sup>-</sup>GL7<sup>+</sup>) and memory B cells (CD3<sup>-</sup>CD138<sup>-</sup>CD19<sup>+</sup>GL7<sup>-</sup>CD38<sup>+</sup>IgD<sup>-</sup>) (<xref rid="vaccines-12-01361-f006" ref-type="fig">Figure 6</xref>A). Compared to unvaccinated controls, both vaccinated IL-17A-depleted and IgG control animals displayed an overall increase in germinal center B cells, with a few exceptions (<xref rid="vaccines-12-01361-f006" ref-type="fig">Figure 6</xref>B), and memory B cells (<xref rid="vaccines-12-01361-f006" ref-type="fig">Figure 6</xref>C), although some did not reach statistically significant levels, and their levels were generally comparable irrespective of IL-17A depletion status. The GC B cell population between IL-17A-depleted and IgG controls only reached significance when animals were vaccinated with LMP-Ad5-YFV (<xref rid="vaccines-12-01361-f006" ref-type="fig">Figure 6</xref>B). Likewise, statistical differences in memory B cells between IL-17A-depleted and IgG controls were only observed when animals were vaccinated with either LMA-LMA or LMA&#x02013;Ad5-YFV (<xref rid="vaccines-12-01361-f006" ref-type="fig">Figure 6</xref>C). </p></sec><sec id="sec3dot3-vaccines-12-01361"><title>3.3. T Cell Responses Are Induced by Vaccination</title><p>To examine the cell-mediated response, splenocytes were isolated from IL-17A-depleted, IgG control, and unvaccinated control animals 4 weeks post-boost vaccination (<xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A) and stained for anti-CD3, -CD4, and -CD8 followed by intracellular staining for various cytokines (IFN&#x003b3;, IL-2, TNF&#x003b1;, IL-4, and IL-17A). Compared to unvaccinated control animals, IL-17A<sup>+</sup> T cells (both CD4<sup>+</sup> and CD8<sup>+</sup>) were at basal levels in immunized and IL-17A-depleted mice, while they were significantly increased in all vaccinated IgG control animals. The highest IL-17A<sup>+</sup> CD4<sup>+</sup> population was observed in IgG control animals vaccinated by the prime-pull strategy (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>A). A similar trend was also observed for IFN&#x003b3;<sup>+</sup> and IL-2<sup>+</sup> T cells in response to vaccination, which were overall much lower in IL-17A-depleted animals compared to IgG controls (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>C&#x02013;F). However, this trend was not observed in TNF&#x003b1;<sup>+</sup> T cell populations, as comparable levels were observed between some IL-17A-depleted and IgG control animals in response to vaccination. Furthermore, the overall TNF&#x003b1;<sup>+</sup> T cell response was only slightly to moderately increased in immunized animals compared to unimmunized controls (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>G&#x02013;H). Interestingly, the production of Th1 cytokine-producing (IL-2 and TNF&#x003b1;) T cells was partially recovered in IL-17A-depleted animals receiving prime-pull vaccinations, reaching significance compared to unimmunized control mice (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>E&#x02013;H). </p><p>Similarly, the overall IL-4<sup>+</sup> T cell response was only slightly to moderately increased in immunized animals compared to unimmunized controls (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>I,J). A significantly higher percentage of IL-4<sup>+</sup> CD4<sup>+</sup> cells in IgG control mice immunized with either LAVs or Ad5-YFV&#x02014;LMA was observed compared to IL-17A-depleted mice, but the opposite pattern was observed in mice vaccinated with Ad5-YFV&#x02013;LMP or LMA&#x02013;Ad5-YFV (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>I). Likewise, the IL-4<sup>+</sup> CD8<sup>+</sup> population was significantly increased in IL-17A-depleted mice compared to IgG control mice in response to immunization with either Ad5-YFV&#x02013;LMP or LMA&#x02013;Ad5-YFV (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>J).</p><p>We also utilized an activation-induced marker (AIM) assay to further examine antigen-activated T cells that might not express sufficient cytokines to be measured by traditional intracellular staining (ICS) methods [<xref rid="B45-vaccines-12-01361" ref-type="bibr">45</xref>]. These T cells were antigen-experienced (CD44<sup>+</sup>) and were further gated with CD134<sup>+</sup>CD25<sup>+</sup> for CD4 or CD69<sup>+</sup>CD25<sup>+</sup> for CD8. Overall, vaccinated mice displayed increased antigen-activated T cells compared to unvaccinated control animals although some did not reach statistically significant levels (<xref rid="vaccines-12-01361-f008" ref-type="fig">Figure 8</xref>A,B). Levels of antigen-activated T cells were generally equivalent between immunized IL-17A-depleted and IgG control mice, except for CD8<sup>+</sup> cells from LMP&#x02013;Ad5-YFV-immunized mice, which were significantly lower in IL-17A-depleted mice.</p><p>We next evaluated central (TCM) and effector (TEM) memory T cell responses. TCM cells interact with antigen-specific dendritic cells in primary lymphoid tissues before expansion to acquire effector functions. TEM cells migrate into secondary lymphoid tissues to interact with pathogens directly and provide cytotoxic functions [<xref rid="B46-vaccines-12-01361" ref-type="bibr">46</xref>]. Compared to unimmunized control animals, the populations of both TCM and TEM cells generally increased after vaccination, although a few did not reach significant levels (<xref rid="vaccines-12-01361-f009" ref-type="fig">Figure 9</xref>A,B). However, comparable levels of memory T cells were observed across the majority of IL-17A-depleted and IgG control groups in response to vaccination. Significant differences were only observed in the Ad5-YFV&#x02013;LMA- or LMP&#x02013;Ad5-YFV-immunized groups for TCM and in Ad5-YFV&#x02013;LMP- or LMA&#x02013;Ad5-YFV-immunized groups for TEM, respectively (<xref rid="vaccines-12-01361-f009" ref-type="fig">Figure 9</xref>A,B).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01361"><title>4. Discussion</title><p>IL-17 family cytokines exhibit diverse biological functions that promote multi-pathogen protective immunity and drive autoimmune and infection-related inflammation [<xref rid="B47-vaccines-12-01361" ref-type="bibr">47</xref>]. The IL-17 family consists of six members, from IL-17A to F, based on sequence homology, with IL-17A and IL-17F sharing the greatest homology (50&#x02013;55%) between them. The corresponding genes of IL-17A and IL-17F are located in close proximity on the same chromosome in both humans and mice [<xref rid="B39-vaccines-12-01361" ref-type="bibr">39</xref>,<xref rid="B48-vaccines-12-01361" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-01361" ref-type="bibr">49</xref>]. IL-17 signaling is initiated by cell membrane receptors composed of five members (IL-17RA to IL-17RE), which function either as homodimeric or heterodimeric proteins characterized by the conserved intracellular domain SEFIR (similar expression to fibroblast growth factor genes) [<xref rid="B50-vaccines-12-01361" ref-type="bibr">50</xref>]. IL-17A, the most widely studied and significant member of the IL-17 family, forms either homodimers alone or heterodimers with IL-17F and binds to a receptor complex of IL-17RA/IL-17RC. These mediate biological and immunological functions mainly through activation of the nuclear factor-kappa B (NF-kB) signaling pathway [<xref rid="B48-vaccines-12-01361" ref-type="bibr">48</xref>,<xref rid="B51-vaccines-12-01361" ref-type="bibr">51</xref>]. </p><p>Th17 cells are the main source of IL-17 family cytokines; however, these cytokines can also be produced by innate immune cells in response to IL-1&#x003b2; and IL-23 stimulation [<xref rid="B47-vaccines-12-01361" ref-type="bibr">47</xref>]. The IL-17 pathway is currently a strategic drug target for many autoimmune and chronic inflammatory disorders. Therapeutic mAbs target IL-17A and F, their receptors, or IL-23, an important cytokine for maintaining the differentiation state of Th17 cells that produce IL-17A and IL-17F. Indeed, antibodies against the above targets are exceedingly effective in many diseases [<xref rid="B47-vaccines-12-01361" ref-type="bibr">47</xref>,<xref rid="B51-vaccines-12-01361" ref-type="bibr">51</xref>]. On the other hand, fungal and bacterial protective immunity is mediated by IL-17, further promoting neutrophil recruitment, antimicrobial peptide production, and maintaining epithelial barrier function [<xref rid="B47-vaccines-12-01361" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-12-01361" ref-type="bibr">48</xref>,<xref rid="B51-vaccines-12-01361" ref-type="bibr">51</xref>]. Importantly, evidence also suggests that Th17 is critical for vaccine-induced immune responses against infectious diseases, especially at the mucosal surface [<xref rid="B52-vaccines-12-01361" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-01361" ref-type="bibr">53</xref>].</p><p>For example, IL-23 and IL-17A have been shown to play a critical role in the expression of vaccine-induced immunity against pulmonary tuberculosis [<xref rid="B54-vaccines-12-01361" ref-type="bibr">54</xref>]. Furthermore, Bacille Calmette Guerin (BCG) vaccination followed by boosting with either viral vector- or plasmid-based mycobacterial protective antigen 85 (Ag85A) elicited greater expression of IL-17A, correlating with better protection compared to BCG vaccination alone in mice and cattle [<xref rid="B55-vaccines-12-01361" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-12-01361" ref-type="bibr">56</xref>]. Interestingly, IL-17A was not detectable in mice primed with DNA Ag85A or vaccinated with BCG alone [<xref rid="B55-vaccines-12-01361" ref-type="bibr">55</xref>]. The lack of protection against pulmonary tuberculosis further suggests that the generation of IL-17A through vaccination may be a prerequisite for the development of a successful long-lasting memory immune response [<xref rid="B52-vaccines-12-01361" ref-type="bibr">52</xref>]. Likewise, the role of IL-17A in vaccine-induced responses against extracellular bacteria such as <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Bordetella pertussis</italic>, <italic toggle="yes">Helicobacter pylori</italic>, and <italic toggle="yes">Pseudomonas aeruginosa</italic> has also been established [<xref rid="B52-vaccines-12-01361" ref-type="bibr">52</xref>].</p><p>Th17 cells are effective helpers for B cells, and blockade of IL-17A signaling significantly reduces germinal centers (GCs) in both number and size, driving B cell isotype class switching to IgG2a and IgG3 subtypes [<xref rid="B57-vaccines-12-01361" ref-type="bibr">57</xref>]. In our study, overall enhanced IgG titers to the F1V fusion protein with a generally balanced Th1/Th2 response were observed in all immunized mice, and animals receiving LAVs as the first dose had slightly higher IgG1 over IgG2a compared to other immunization strategies (<xref rid="vaccines-12-01361-f002" ref-type="fig">Figure 2</xref>). A similar phenomenon was also observed in our previous study [<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>]. In addition, both immunized IL-17A-depleted and IgG control mice had comparable levels of GCs and memory B cells (<xref rid="vaccines-12-01361-f006" ref-type="fig">Figure 6</xref>). However, significantly higher serum IgG titers to either F1V or F1 were noted in immunized IL-17A-depleted mice. In contrast, antibody titers to YscF were significantly lower in immunized mice when IL-17A was depleted (<xref rid="vaccines-12-01361-f002" ref-type="fig">Figure 2</xref> and <xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>). Clearly, the class switching of IgG isotypes, GC activities, and serum IgG titers appeared to be more associated with antigen-specific response, or type of vaccine, rather than IL-17A depletion. The differences between this study and a previous study [<xref rid="B57-vaccines-12-01361" ref-type="bibr">57</xref>] could be related to different stimulating antigens, mouse strains, and immunological methods used. In our study, we utilized Swiss Webster outbred mice, LAVs alone or in combination with Ad5-YFV, and flow cytometry for GC activities, while others utilized <italic toggle="yes">in vitro</italic> assays along with C57BL/6 mice, myelin oligodendrocyte glycoprotein (MOG35-55) peptide, and immunofluorescence staining for GCs [<xref rid="B57-vaccines-12-01361" ref-type="bibr">57</xref>]. </p><p>The specific reasons for the opposite antibody titer patterns to F1 and YscF in IL-17A-depleted mice are not clear; however, intertwined roles and functions of IL-17A and IL-17F are plausible. In certain clinical cases, targeting IL-17A alone may not be enough to control disease long term [<xref rid="B58-vaccines-12-01361" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-12-01361" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01361" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-12-01361" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-12-01361" ref-type="bibr">62</xref>]; therefore, inhibition of both IL-17A and F might be preferable [<xref rid="B39-vaccines-12-01361" ref-type="bibr">39</xref>]. Activated Th17 cells also differ in the subtype of IL-17 that they preferentially express: IL-17A, IL-17A/F, or IL-17F. Th17 differentiation is typically controlled by three factors: cytokine environment, strength or concentration of antigenic signaling through the T cell receptor (TCR), and stimulus duration [<xref rid="B63-vaccines-12-01361" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-12-01361" ref-type="bibr">64</xref>]. For example, the IL-17A<sup>+</sup> subpopulation is preferentially promoted through low-strength T cell activation, whereas the IL-17F<sup>+</sup> subpopulation is preferentially promoted through high-strength stimulation [<xref rid="B39-vaccines-12-01361" ref-type="bibr">39</xref>]. Therefore, differing antibody titers to F1 and YscF could be related to the strengths associated with either IL-17A<sup>+</sup> or IL-17F<sup>+</sup> subpopulations. </p><p>Interestingly, compared to immunized IgG control mice, overall IgA titers to all three examined antigens were either at comparable levels or lower in IL-17A-depleted mice (<xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>), suggesting the influence of IL-17A was more obvious in production of mucosal IgA rather than serum IgG. This could be related to a cytokine environment that is more favorable to IL-17A<sup>+</sup> subpopulations in the mucosa, providing evidence that Th17 is more critical for vaccine-induced immune responses against mucosal infectious diseases [<xref rid="B52-vaccines-12-01361" ref-type="bibr">52</xref>,<xref rid="B54-vaccines-12-01361" ref-type="bibr">54</xref>]. It must be mentioned that induction of an IL-17A response was only observed in mice immunized with either our LAVs alone or in combination with Ad5-YFV and was not seen in mice vaccinated with Ad5-YFV alone [<xref rid="B9-vaccines-12-01361" ref-type="bibr">9</xref>,<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>]. Therefore, unidentified antigens in our LAVs could potentially be responsible for the induction of IL-17A, and F1, LcrV, and YscF may not play a significant role. Nevertheless, our vaccines induced strong humoral and mucosal immunity in mice irrespective of IL-17A depletion. </p><p>Neutralizing antibodies are integral in directly inhibiting the transmission or infectivity of pathogens by interacting with specific epitopes on antigens [<xref rid="B65-vaccines-12-01361" ref-type="bibr">65</xref>]. Studies have shown that certain epitope-specific antibodies restrict the mobility of <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B66-vaccines-12-01361" ref-type="bibr">66</xref>], <italic toggle="yes">Vibrio cholerae</italic> [<xref rid="B67-vaccines-12-01361" ref-type="bibr">67</xref>], and <italic toggle="yes">Salmonella enterica</italic> [<xref rid="B68-vaccines-12-01361" ref-type="bibr">68</xref>]<bold>,</bold> thereby decreasing their ability to infect host cells. mAbs targeting the <italic toggle="yes">Y. pestis</italic> F1 capsular antigen have been identified, exhibiting high binding affinity, epitope specificity, and protective efficacy against bubonic and pneumonic challenges [<xref rid="B69-vaccines-12-01361" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-12-01361" ref-type="bibr">70</xref>]. In addition, two mAbs targeting <italic toggle="yes">Y. pestis</italic> LcrV, 7.3 and 29.3, were shown to have high binding affinity and neutralizing activity [<xref rid="B44-vaccines-12-01361" ref-type="bibr">44</xref>]. Mab7.3 binds to the region spanning amino acids 135&#x02013;275 and, while much less is known about Mab29.3, it binds to a region near the Mab7.3 epitope on LcrV [<xref rid="B44-vaccines-12-01361" ref-type="bibr">44</xref>]. While 50 &#x003bc;g LcrV Mab7.3 administered 24 h post-bubonic challenge provided 100% protection to mice, administration of 50 &#x003bc;g LcrV Mab29.3 provided 80% protection [<xref rid="B44-vaccines-12-01361" ref-type="bibr">44</xref>]. Furthermore, the protective efficacy of Mab7.3 has also been demonstrated in different species of mice infected with various <italic toggle="yes">Y. pestis</italic> strains, including CO92, in both bubonic and pneumonic plague models [<xref rid="B44-vaccines-12-01361" ref-type="bibr">44</xref>]. Humanized Mab7.3 is currently being produced for therapeutic usage [<xref rid="B44-vaccines-12-01361" ref-type="bibr">44</xref>].</p><p>To quantify neutralizing antibodies in the sera of immunized mice, competitive ELISAs with biotinylated LcrV Mab7.3 were utilized. Higher levels of LcrV-neutralizing antibodies were detected in all immunized mice compared to unimmunized controls (<xref rid="vaccines-12-01361-f004" ref-type="fig">Figure 4</xref>). Heterologous vaccination, where Ad5-YFV was administered first, as opposed to the LAVs, elicited slightly higher LcrV-neutralizing antibodies (<xref rid="vaccines-12-01361-f004" ref-type="fig">Figure 4</xref>). This could be due to conformational differences in LcrV between the LAVs and the adenovirus-based YFV fusion protein. The LcrV epitope recognized by Mab7.3 could be better presented by antigen-presenting cells (APCs) in Ad5-YFV rather than in its natural form within the LAVs. In addition, access to LcrV on the surface of <italic toggle="yes">Y. pestis</italic> could also be masked by other bacterial components, such as the F1 capsule. Therefore, the clear presentation of LcrV epitopes by Ad5-YFV would eventually lead to a better antibody response. As also noted in <xref rid="vaccines-12-01361-f004" ref-type="fig">Figure 4</xref>, neutralizing antibody titers were higher in vaccinated IgG controls compared to IL-17A-depleted animals, in contrast to the comparable serum LcrV antibody titers between these groups (<xref rid="vaccines-12-01361-f003" ref-type="fig">Figure 3</xref>). The strength of antigen epitopes may also determine their association with either IL-17A<sup>+</sup> or IL-17F<sup>+</sup> subpopulations, as discussed for F1 and YscF above. </p><p>Compared to vaccine-induced antibody production, a clearer trend was observed for the influence of IL-17A on T cell responses during immunization. More specifically, T cells positive for IL-17A, IFN&#x003b3;, and IL-2 were all significantly lower in IL-17A-depleted mice (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>A&#x02013;F). Impaired IFN&#x003b3; production was also evidenced in mycobacterial-specific T cells from IL-17A-deficient mice [<xref rid="B71-vaccines-12-01361" ref-type="bibr">71</xref>]. The frequency of Ag-specific IFN&#x003b3;&#x02013;producing lung T cells and Th1 cell recruitment was significantly reduced when IL-17A was neutralized in vaccinated mice during <italic toggle="yes">Mycobacterium tuberculosis</italic> challenge [<xref rid="B54-vaccines-12-01361" ref-type="bibr">54</xref>]. </p><p>Similarly, IL-17A is required for the generation of protective IFN&#x003b3; responses during pulmonary tularemia [<xref rid="B72-vaccines-12-01361" ref-type="bibr">72</xref>]. The correlation of IL-17A- and IFN&#x003b3;-producing T cells seen in various bacterial infections may be related to the <italic toggle="yes">in vivo</italic> plasticity of Th17 cells, where cytokine production can switch from predominantly producing IL-17 to IFN&#x003b3;, thereby resembling Th1 cells [<xref rid="B47-vaccines-12-01361" ref-type="bibr">47</xref>,<xref rid="B73-vaccines-12-01361" ref-type="bibr">73</xref>]. In addition, IL-4 suppresses the reactivation of committed Th17 cells, even in the presence of TGF-&#x003b2;, IL-6, and IL-23. Further, signal transducer and activator of transcription 6 (STAT6)-dependent IL-4 down-regulation of IL-17A is mediated by inhibition of STAT3 binding at the IL-17A promoter [<xref rid="B74-vaccines-12-01361" ref-type="bibr">74</xref>]. Although IFN&#x003b3; expression by Th17 cells is induced by Th1 cytokines, IL-4 does not induce a Th2 phenotype in Th17 cells. As such, a correlation between IL-17A and IFN&#x003b3; was not observed with the Th2 cytokine IL-4 [<xref rid="B74-vaccines-12-01361" ref-type="bibr">74</xref>]. Indeed, our data suggested that the influence of IL-17A on IL-4<sup>+</sup> T cell populations seemed to depend on the type of vaccine the animals received and there was no clear pattern related to IL-17A depletion (<xref rid="vaccines-12-01361-f007" ref-type="fig">Figure 7</xref>I&#x02013;J).</p><p>The significant reduction in Th1<sup>+</sup> T cells in IL-17A-depleted mice prompted us to further evaluate overall T cell activation using the AIM assay, based on T cell receptor-stimulated surface markers [<xref rid="B45-vaccines-12-01361" ref-type="bibr">45</xref>]. These markers determine overall T cell activation, rather than only specific cytokine markers utilized with traditional staining techniques [<xref rid="B75-vaccines-12-01361" ref-type="bibr">75</xref>]. While there were no differences between IL-17A-depleted and IgG control animals, vaccinated mice displayed an overall increase in activated antigen-specific T cells (<xref rid="vaccines-12-01361-f008" ref-type="fig">Figure 8</xref>). A similar pattern was observed for memory T cells as their overall levels were comparable in both immunized IL-17A-depleted and IgG control animals (<xref rid="vaccines-12-01361-f009" ref-type="fig">Figure 9</xref>A,B). </p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01361"><title>5. Conclusions</title><p>In summary, the depletion of IL-17A clearly demonstrated impacts on both humoral and cellular immune responses elicited by our vaccines; however, the overall immunity associated with vaccination in IL-17A-depleted mice was adequate to protect them from lethal <italic toggle="yes">Y. pestis</italic> CO92 challenge. Our earlier study also demonstrated that heterologous vaccination with Ad5-YFV and LMA protected mice against lethal challenge with the non-encapsulated <italic toggle="yes">Y. pestis</italic> (F1<sup>-</sup>) CO92 strain [<xref rid="B40-vaccines-12-01361" ref-type="bibr">40</xref>]; therefore, a similar study in IL-17-depleted mice will be conducted in the future to further evaluate the efficiency of our vaccines against different strains of <italic toggle="yes">Y. pestis</italic>. In addition to promoting neutrophil recruitment, producing antimicrobial peptides, and maintaining epithelial barrier function, IL-17 is also closely associated with host defense responses by promoting tertiary immunity in lymphoid tissues [<xref rid="B38-vaccines-12-01361" ref-type="bibr">38</xref>]. For example, it promotes bronchus-associated lymphoid tissue immunity against the intracellular pathogen <italic toggle="yes">M. tuberculosis</italic> [<xref rid="B54-vaccines-12-01361" ref-type="bibr">54</xref>,<xref rid="B76-vaccines-12-01361" ref-type="bibr">76</xref>]. Furthermore, studies in a <italic toggle="yes">B. pertussis</italic> infection mouse model showed that antigen-specific Th17 cells in nasal tissue predominantly produced IL-17 without IFN&#x003b3; and persisted as tissue-resident memory T (TRM) cells for many months after bacterial clearance [<xref rid="B77-vaccines-12-01361" ref-type="bibr">77</xref>]. Therefore, the evaluation of local lung immunity, e.g., local B and T cell levels in response to our vaccines in both IL-17A and IL-17F depleted animals, could shed more light on the role of IL-17 in modulating acquired immunity. </p><p>It is worth pointing out that several recent studies have reported the effects of sex-based differences on the efficacy of plague vaccines, where female mice generated better immunity in response to vaccination than males [<xref rid="B78-vaccines-12-01361" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-12-01361" ref-type="bibr">79</xref>]. Therefore, our future studies will use animals balanced by sex, as in our recently published phage therapy study for <italic toggle="yes">Y. pestis</italic> infection [<xref rid="B80-vaccines-12-01361" ref-type="bibr">80</xref>]. We must emphasize that the conclusions of this study originate from a mouse model. While the biological functions of murine and human IL-17 are very similar [<xref rid="B47-vaccines-12-01361" ref-type="bibr">47</xref>,<xref rid="B81-vaccines-12-01361" ref-type="bibr">81</xref>], subtle differences in IL-17-related pathways, including IL-17 ligand&#x02013;receptor interactions [<xref rid="B82-vaccines-12-01361" ref-type="bibr">82</xref>], IL-17-producing cell type differentiation and stabilization [<xref rid="B83-vaccines-12-01361" ref-type="bibr">83</xref>], and genetic diversity [<xref rid="B84-vaccines-12-01361" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-12-01361" ref-type="bibr">85</xref>], have been observed between mice and humans. Therefore, evaluation of our vaccines in higher animal models, as we previously conducted for Ad5-YFV in nonhuman primates [<xref rid="B10-vaccines-12-01361" ref-type="bibr">10</xref>], is warranted and will be included in our future studies. </p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank Diane Williamson and Thomas Laws of the Defence Science and Technology Laboratory, Porton Down, Salisbury, UK for generously providing the LcrV Mab7.3 antibody. Methodology figures created with Biorender.com (2024).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, E.K.H., J.S., and A.K.C.; methodology, E.K.H., J.S., and A.K.C.; investigation, E.K.H., J.S., P.B.K., B.H.N., A.K.V., and A.K.C.; visualization, E.K.H.; formal analysis, E.K.H.; funding acquisition, A.K.C.; supervision, A.K.C.; writing&#x02014;original draft preparation, E.K.H., J.S., and A.K.C.; writing&#x02014;review and editing, E.K.H., J.S. and A.K.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All animal studies were ethically performed under an approved Institutional Animal Care and Use Committee (IACUC) protocol (Office of Laboratory Animal Welfare assurance number A3314-01).</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01361"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perry</surname><given-names>R.D.</given-names></name>
<name><surname>Fetherston</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Yersinia pestis&#x02014;Etiologic agent of plague</article-title><source>Clin. Microbiol. Rev.</source><year>1997</year><volume>10</volume><fpage>35</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1128/CMR.10.1.35</pub-id><pub-id pub-id-type="pmid">8993858</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01361"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williamson</surname><given-names>E.D.</given-names></name>
<name><surname>Kilgore</surname><given-names>P.B.</given-names></name>
<name><surname>Hendrix</surname><given-names>E.K.</given-names></name>
<name><surname>Neil</surname><given-names>B.H.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Progress on the research and development of plague vaccines with a call to action</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>162</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00958-1</pub-id><pub-id pub-id-type="pmid">39242587</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01361"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>C.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Yersinia pestis antibiotic resistance: A systematic review</article-title><source>Osong Public Health Res. Perspect.</source><year>2022</year><volume>13</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.24171/j.phrp.2021.0288</pub-id><pub-id pub-id-type="pmid">35255676</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01361"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenzweig</surname><given-names>J.A.</given-names></name>
<name><surname>Hendrix</surname><given-names>E.K.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Plague vaccines: New developments in an ongoing search</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2021</year><volume>105</volume><fpage>4931</fpage><lpage>4941</lpage><pub-id pub-id-type="doi">10.1007/s00253-021-11389-6</pub-id><pub-id pub-id-type="pmid">34142207</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01361"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feodorova</surname><given-names>V.A.</given-names></name>
<name><surname>Lyapina</surname><given-names>A.M.</given-names></name>
<name><surname>Khizhnyakova</surname><given-names>M.A.</given-names></name>
<name><surname>Zaitsev</surname><given-names>S.S.</given-names></name>
<name><surname>Sayapina</surname><given-names>L.V.</given-names></name>
<name><surname>Arseneva</surname><given-names>T.E.</given-names></name>
<name><surname>Trukhachev</surname><given-names>A.L.</given-names></name>
<name><surname>Lebedeva</surname><given-names>S.A.</given-names></name>
<name><surname>Telepnev</surname><given-names>M.V.</given-names></name>
<name><surname>Ulianova</surname><given-names>O.V.</given-names></name>
<etal/>
</person-group><article-title>Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine</article-title><source>PLoS Neglected Trop. Dis.</source><year>2018</year><volume>12</volume><elocation-id>e0006511</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006511</pub-id><pub-id pub-id-type="pmid">29889829</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01361"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cote</surname><given-names>C.K.</given-names></name>
<name><surname>Biryukov</surname><given-names>S.S.</given-names></name>
<name><surname>Klimko</surname><given-names>C.P.</given-names></name>
<name><surname>Shoe</surname><given-names>J.L.</given-names></name>
<name><surname>Hunter</surname><given-names>M.</given-names></name>
<name><surname>Rosario-Acevedo</surname><given-names>R.</given-names></name>
<name><surname>Fetterer</surname><given-names>D.P.</given-names></name>
<name><surname>Moody</surname><given-names>K.L.</given-names></name>
<name><surname>Meyer</surname><given-names>J.R.</given-names></name>
<name><surname>Rill</surname><given-names>N.O.</given-names></name>
<etal/>
</person-group><article-title>Protection elicited by attenuated live Yersinia pestis vaccine strains against lethal infection with virulent Y. pestis</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>161</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020161</pub-id><pub-id pub-id-type="pmid">33669472</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01361"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiner</surname><given-names>B.L.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Ponnusamy</surname><given-names>D.</given-names></name>
<name><surname>Baze</surname><given-names>W.B.</given-names></name>
<name><surname>Fitts</surname><given-names>E.C.</given-names></name>
<name><surname>Popov</surname><given-names>V.L.</given-names></name>
<name><surname>Van Lier</surname><given-names>C.J.</given-names></name>
<name><surname>Erova</surname><given-names>T.E.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Intramuscular immunization of mice with a live-Attenuated triple mutant of yersinia pestis co92 induces robust humoral and cell-mediated immunity to completely protect animals against pneumonic plague</article-title><source>Clin. Vaccine Immunol.</source><year>2015</year><volume>22</volume><fpage>1255</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1128/CVI.00499-15</pub-id><pub-id pub-id-type="pmid">26446423</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01361"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiner</surname><given-names>B.L.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Cong</surname><given-names>Y.</given-names></name>
<name><surname>Kirtley</surname><given-names>M.L.</given-names></name>
<name><surname>Andersson</surname><given-names>J.A.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague</article-title><source>NPJ Vaccines</source><year>2016</year><volume>1</volume><fpage>16020</fpage><pub-id pub-id-type="doi">10.1038/npjvaccines.2016.20</pub-id><pub-id pub-id-type="pmid">29263858</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01361"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kilgore</surname><given-names>P.B.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Andersson</surname><given-names>J.A.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-00275-3</pub-id><pub-id pub-id-type="pmid">33514747</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01361"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Kirtley</surname><given-names>M.L.</given-names></name>
<name><surname>Klages</surname><given-names>C.</given-names></name>
<name><surname>Erova</surname><given-names>T.E.</given-names></name>
<name><surname>Telepnev</surname><given-names>M.</given-names></name>
<name><surname>Ponnusamy</surname><given-names>D.</given-names></name>
<name><surname>Fitts</surname><given-names>E.C.</given-names></name>
<name><surname>Baze</surname><given-names>W.B.</given-names></name>
<name><surname>Sivasubramani</surname><given-names>S.K.</given-names></name>
<name><surname>Lawrence</surname><given-names>W.S.</given-names></name>
<etal/>
</person-group><article-title>A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates</article-title><source>Clin. Vaccine Immunol.</source><year>2016</year><volume>23</volume><fpage>586</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1128/CVI.00150-16</pub-id><pub-id pub-id-type="pmid">27170642</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01361"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tao</surname><given-names>P.</given-names></name>
<name><surname>Mahalingam</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Moayeri</surname><given-names>M.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Lawrence</surname><given-names>W.S.</given-names></name>
<name><surname>Leppla</surname><given-names>S.H.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
<name><surname>Rao</surname><given-names>V.B.</given-names></name>
</person-group><article-title>A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e01926-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01926-18</pub-id><pub-id pub-id-type="pmid">30327445</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01361"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanapala</surname><given-names>S.</given-names></name>
<name><surname>Rahav</surname><given-names>H.</given-names></name>
<name><surname>Patel</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
</person-group><article-title>Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2410</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.094</pub-id><pub-id pub-id-type="pmid">27060051</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01361"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morton</surname><given-names>M.</given-names></name>
<name><surname>Garmory</surname><given-names>H.S.</given-names></name>
<name><surname>Perkins</surname><given-names>S.D.</given-names></name>
<name><surname>O&#x02019;Dowd</surname><given-names>A.M.</given-names></name>
<name><surname>Griffin</surname><given-names>K.F.</given-names></name>
<name><surname>Turner</surname><given-names>A.K.</given-names></name>
<name><surname>Bennett</surname><given-names>A.M.</given-names></name>
<name><surname>Titball</surname><given-names>R.W.</given-names></name>
</person-group><article-title>A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2524</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.007</pub-id><pub-id pub-id-type="pmid">15193377</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01361"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biryukov</surname><given-names>S.</given-names></name>
<name><surname>Dankmeyer</surname><given-names>J.L.</given-names></name>
<name><surname>Shamsuddin</surname><given-names>Z.</given-names></name>
<name><surname>Velez</surname><given-names>I.</given-names></name>
<name><surname>Rill</surname><given-names>N.O.</given-names></name>
<name><surname>Rosario-Acevedo</surname><given-names>R.</given-names></name>
<name><surname>Klimko</surname><given-names>C.P.</given-names></name>
<name><surname>Shoe</surname><given-names>J.L.</given-names></name>
<name><surname>Hunter</surname><given-names>M.</given-names></name>
<name><surname>Ward</surname><given-names>M.D.</given-names></name>
<etal/>
</person-group><article-title>Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the Yersinia pestis Plague rF1V Vaccine</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>726416</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.726416</pub-id><pub-id pub-id-type="pmid">34512658</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01361"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heath</surname><given-names>D.G.</given-names></name>
<name><surname>Anderson</surname><given-names>G.W.</given-names></name>
<name><surname>Matthew Mauroj</surname><given-names>J.</given-names></name>
<name><surname>Welkos</surname><given-names>S.L.</given-names></name>
<name><surname>Andrews</surname><given-names>G.P.</given-names></name>
<name><surname>Adamovicz</surname><given-names>J.</given-names></name>
<name><surname>Friedlander</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Protection against experimental bubonic and pneumonic plague by a recombinant capsular Fl-V antigen fusion protein vaccine</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)80110-2</pub-id><pub-id pub-id-type="pmid">9682370</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01361"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albrecht</surname><given-names>M.T.</given-names></name>
<name><surname>Eyles</surname><given-names>J.E.</given-names></name>
<name><surname>Baillie</surname><given-names>L.W.</given-names></name>
<name><surname>Keane-Myers</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2012</year><volume>65</volume><fpage>505</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2012.00974.x</pub-id><pub-id pub-id-type="pmid">22515653</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01361"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shattock</surname><given-names>R.J.</given-names></name>
<name><surname>Andrianaivoarimanana</surname><given-names>V.</given-names></name>
<name><surname>McKay</surname><given-names>P.F.</given-names></name>
<name><surname>Randriantseheno</surname><given-names>L.N.</given-names></name>
<name><surname>Murugaiah</surname><given-names>V.</given-names></name>
<name><surname>Samnuan</surname><given-names>K.</given-names></name>
<name><surname>Rogers</surname><given-names>P.</given-names></name>
<name><surname>Tregoning</surname><given-names>J.S.</given-names></name>
<name><surname>Rajerison</surname><given-names>M.</given-names></name>
<name><surname>Moore</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>1247041</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1247041</pub-id><pub-id pub-id-type="pmid">38029221</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01361"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kon</surname><given-names>E.</given-names></name>
<name><surname>Levy</surname><given-names>Y.</given-names></name>
<name><surname>Elia</surname><given-names>U.</given-names></name>
<name><surname>Cohen</surname><given-names>H.</given-names></name>
<name><surname>Hazan-Halevy</surname><given-names>I.</given-names></name>
<name><surname>Aftalion</surname><given-names>M.</given-names></name>
<name><surname>Ezra</surname><given-names>A.</given-names></name>
<name><surname>Bar-Haim</surname><given-names>E.</given-names></name>
<name><surname>Naidu</surname><given-names>G.S.</given-names></name>
<name><surname>Diesendruck</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium</article-title><source>Sci. Adv.</source><year>2023</year><volume>9</volume><fpage>eadg1036</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adg1036</pub-id><pub-id pub-id-type="pmid">36888708</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01361"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feodorova</surname><given-names>V.A.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
</person-group><article-title>Plague vaccines: Current developments and future perspectives</article-title><source>Emerg. Microbes Infect.</source><year>2012</year><volume>1</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/emi.2012.34</pub-id></element-citation></ref><ref id="B20-vaccines-12-01361"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Singh</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Plague vaccine: Recent progress and prospects</article-title><source>NPJ Vaccines</source><year>2019</year><volume>4</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0105-9</pub-id><pub-id pub-id-type="pmid">30792905</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01361"><label>21.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>DynPort Vaccine Company Llc, A.G.C</collab>
</person-group><article-title>Safety, Tolerability &#x00026; Immunogenicity of the Recombinant Plague Vaccine rF1V</article-title><year>2006</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00097396?term=Safety,%20Tolerability%20%26%20Immunogenicity%20of%20the%20Recombinant%20Plague%20Vaccine%20rF1V&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00097396?term=Safety,%20Tolerability%20%26%20Immunogenicity%20of%20the%20Recombinant%20Plague%20Vaccine%20rF1V&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B22-vaccines-12-01361"><label>22.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>DynPort Vaccine Company Llc, A.G.C</collab>
</person-group><article-title>Recombinant Plague Vaccine rF1V in Healthy Volunteers</article-title><source>ClinicalTrials.gov</source><year>2008</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00332956?term=Recombinant%20Plague%20Vaccine%20rF1V%20in%20Healthy%20Volunteers.%20&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00332956?term=Recombinant%20Plague%20Vaccine%20rF1V%20in%20Healthy%20Volunteers.%20&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B23-vaccines-12-01361"><label>23.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>DynPort Vaccine Company Llc, A.G.C</collab>
</person-group><article-title>Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant</article-title><source>ClinicalTrials.gov</source><year>2012</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT01122784?term=Randomized%20Single-Blinded%20Study%20to%20Evaluate%20Safety%20and%20Immunogenicity%20of%20Recombinant%20Plague%20Vaccine%20With%20and%20Without%20Adjuvant.%20&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01122784?term=Randomized%20Single-Blinded%20Study%20to%20Evaluate%20Safety%20and%20Immunogenicity%20of%20Recombinant%20Plague%20Vaccine%20With%20and%20Without%20Adjuvant.%20&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B24-vaccines-12-01361"><label>24.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<name><surname>PharmAthene</surname><given-names>U.K.L.</given-names></name>
</person-group><article-title>One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)</article-title><source>ClinicalTrials.gov</source><year>2007</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00246467?term=One%20Year%20Study%20to%20Evaluate%20Three%20Different%20Adjuvanted%20Doses%20of%20the%20Recombinant%20Plague%20Vaccine%20&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00246467?term=One%20Year%20Study%20to%20Evaluate%20Three%20Different%20Adjuvanted%20Doses%20of%20the%20Recombinant%20Plague%20Vaccine%20&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B25-vaccines-12-01361"><label>25.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Diseases, N.I.o.A.a.I</collab>
</person-group><article-title>Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers</article-title><source>ClinicalTrials.gov</source><year>2014</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT01381744?term=.%20Dose%20Escalation%20Trial%20of%20a%20Plague%20Vaccine,%20Flagellin%2FF1%2FV,%20in%20Healthy%20Adult%20Volunteers.%20&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01381744?term=.%20Dose%20Escalation%20Trial%20of%20a%20Plague%20Vaccine,%20Flagellin%2FF1%2FV,%20in%20Healthy%20Adult%20Volunteers.%20&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B26-vaccines-12-01361"><label>26.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<name><surname>Jiangsu Province Centers for Disease Control and</surname><given-names>P.</given-names></name>
</person-group><article-title>Immunogenicity and Safety of Subunit Plague Vaccine</article-title><source>ClinicalTrials.gov</source><year>2015</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT02596308?term=.%20Immunogenicity%20and%20Safety%20of%20Subunit%20Plague%20Vaccine&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02596308?term=.%20Immunogenicity%20and%20Safety%20of%20Subunit%20Plague%20Vaccine&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B27-vaccines-12-01361"><label>27.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Jiangsu Province Centers for Disease Control and, P</collab>
</person-group><article-title>Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens</article-title><source>ClinicalTrials.gov</source><year>2022</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT05330624?term=.%20Immunogenicity%20and%20Safety%20of%20Subunit%20Vaccine%20of%20Plague%20Vaccine%20With%20Two%20Immunization%20Regimens&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05330624?term=.%20Immunogenicity%20and%20Safety%20of%20Subunit%20Vaccine%20of%20Plague%20Vaccine%20With%20Two%20Immunization%20Regimens&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B28-vaccines-12-01361"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>OV Group</collab>
</person-group><source>Investigating a Vaccine Against Plague (PlaVac)</source><publisher-name>Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2021</year><fpage>1</fpage><lpage>21</lpage></element-citation></ref><ref id="B29-vaccines-12-01361"><label>29.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<name><surname>Dynavax Technologies</surname><given-names>C.</given-names></name>
</person-group><article-title>Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018&#x000ae; Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age</article-title><source>ClinicalTrials.gov</source><year>2024</year><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT05506969?term=Trial%20of%20the%20Immunogenicity,%20Safety,%20and%20Tolerability%20of%20rF1V%20Vaccine%20With%20CpG%201018%20Adjuvant%20Compared%20With%20rF1V%20Vaccine&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05506969?term=Trial%20of%20the%20Immunogenicity,%20Safety,%20and%20Tolerability%20of%20rF1V%20Vaccine%20With%20CpG%201018%20Adjuvant%20Compared%20With%20rF1V%20Vaccine&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-29">(accessed on 29 September 2023)</date-in-citation></element-citation></ref><ref id="B30-vaccines-12-01361"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Endsley</surname><given-names>J.J.</given-names></name>
<name><surname>Kirtley</surname><given-names>M.L.</given-names></name>
<name><surname>Foltz</surname><given-names>S.M.</given-names></name>
<name><surname>Huante</surname><given-names>M.B.</given-names></name>
<name><surname>Erova</surname><given-names>T.E.</given-names></name>
<name><surname>Kozlova</surname><given-names>E.V.</given-names></name>
<name><surname>Popov</surname><given-names>V.L.</given-names></name>
<name><surname>Yeager</surname><given-names>L.A.</given-names></name>
<name><surname>Zudina</surname><given-names>I.V.</given-names></name>
<etal/>
</person-group><article-title>Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks</article-title><source>J. Clin. Microbiol.</source><year>2011</year><volume>49</volume><fpage>1708</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1128/JCM.00064-11</pub-id><pub-id pub-id-type="pmid">21367990</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01361"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Meka-Mechenko</surname><given-names>T.V.</given-names></name>
</person-group><article-title>F1-negative natural Y. pestis Strains</article-title><source>Advances in Experimental Medicine and Biology</source><publisher-name>Springer</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>1967</year></element-citation></ref><ref id="B32-vaccines-12-01361"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiner</surname><given-names>B.L.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Kirtley</surname><given-names>M.L.</given-names></name>
<name><surname>Erova</surname><given-names>T.E.</given-names></name>
<name><surname>Popov</surname><given-names>V.L.</given-names></name>
<name><surname>Baze</surname><given-names>W.B.</given-names></name>
<name><surname>van Lier</surname><given-names>C.J.</given-names></name>
<name><surname>Ponnusamy</surname><given-names>D.</given-names></name>
<name><surname>Andersson</surname><given-names>J.A.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
<etal/>
</person-group><article-title>Combinational deletion of three membrane protein-encoding genes highly attenuates Yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>1318</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1128/IAI.02778-14</pub-id><pub-id pub-id-type="pmid">25605764</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01361"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Rosenzweig</surname><given-names>J.A.</given-names></name>
<name><surname>Kirtley</surname><given-names>M.L.</given-names></name>
<name><surname>van Lier</surname><given-names>C.J.</given-names></name>
<name><surname>Fitts</surname><given-names>E.C.</given-names></name>
<name><surname>Kozlova</surname><given-names>E.V.</given-names></name>
<name><surname>Erova</surname><given-names>T.E.</given-names></name>
<name><surname>Tiner</surname><given-names>B.L.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague</article-title><source>Microb. Pathog.</source><year>2013</year><volume>55</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2012.09.011</pub-id><pub-id pub-id-type="pmid">23063826</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01361"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Lier</surname><given-names>C.J.</given-names></name>
<name><surname>Tiner</surname><given-names>B.L.</given-names></name>
<name><surname>Chauhan</surname><given-names>S.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
<name><surname>Fitts</surname><given-names>E.C.</given-names></name>
<name><surname>Huante</surname><given-names>M.B.</given-names></name>
<name><surname>Endsley</surname><given-names>J.J.</given-names></name>
<name><surname>Ponnusamy</surname><given-names>D.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages</article-title><source>Microb. Pathog.</source><year>2015</year><volume>80</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2015.02.005</pub-id><pub-id pub-id-type="pmid">25697665</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01361"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matson</surname><given-names>J.S.</given-names></name>
<name><surname>Durick</surname><given-names>K.A.</given-names></name>
<name><surname>Bradley</surname><given-names>D.S.</given-names></name>
<name><surname>Nilles</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Immunization of mice with YscF provides protection from Yersinia pestis infections</article-title><source>BMC Microbiol.</source><year>2005</year><volume>5</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-5-38</pub-id><pub-id pub-id-type="pmid">15978133</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01361"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swietnicki</surname><given-names>W.</given-names></name>
<name><surname>Powell</surname><given-names>B.S.</given-names></name>
<name><surname>Goodin</surname><given-names>J.</given-names></name>
</person-group><article-title>Yersinia pestis Yop secretion protein F: Purification, characterization, and protective efficacy against bubonic plague</article-title><source>Protein Expr. Purif.</source><year>2005</year><volume>42</volume><fpage>166</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2005.02.016</pub-id><pub-id pub-id-type="pmid">15939303</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01361"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lathem</surname><given-names>W.W.</given-names></name>
<name><surname>Price</surname><given-names>P.A.</given-names></name>
<name><surname>Miller</surname><given-names>V.L.</given-names></name>
<name><surname>Goldman</surname><given-names>W.E.</given-names></name>
</person-group><article-title>A plasminogen-activating protease specifically controls the development of primary pneumonic plague</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1126/science.1137195</pub-id><pub-id pub-id-type="pmid">17255510</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01361"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bi</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>IL-17A Produced by Neutrophils Protects against Pneumonic Plague through Orchestrating IFN-&#x003b3;&#x02013;Activated Macrophage Programming</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>704</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301687</pub-id><pub-id pub-id-type="pmid">24337746</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01361"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>J.-S.</given-names></name>
<name><surname>Kummer</surname><given-names>L.W.</given-names></name>
<name><surname>Szaba</surname><given-names>F.M.</given-names></name>
<name><surname>Smiley</surname><given-names>S.T.</given-names></name>
</person-group><article-title>IL-17 Contributes to Cell-Mediated Defense against Pulmonary Yersinia pestis Infection</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>1675</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003303</pub-id><pub-id pub-id-type="pmid">21172869</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01361"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kilgore</surname><given-names>P.B.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Hendrix</surname><given-names>E.K.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
<name><surname>Chopra</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague</article-title><source>mBio</source><year>2021</year><volume>12</volume><fpage>e03223-21</fpage><pub-id pub-id-type="doi">10.1128/mBio.03223-21</pub-id><pub-id pub-id-type="pmid">34872353</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01361"><label>41.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>ThermoScientific</collab>
</person-group><article-title>Instructions EZ-Link Sulfo-NHS-Biotin</article-title><comment>Available online: <ext-link xlink:href="https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0016134_2161850_EZLinkSulfoNHS_Biotin_UG.pdf" ext-link-type="uri">https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0016134_2161850_EZLinkSulfoNHS_Biotin_UG.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-27">(accessed on 27 November 2024)</date-in-citation></element-citation></ref><ref id="B42-vaccines-12-01361"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williamson</surname><given-names>E.D.</given-names></name>
<name><surname>Flick-Smith</surname><given-names>H.C.</given-names></name>
<name><surname>Waters</surname><given-names>E.</given-names></name>
<name><surname>Miller</surname><given-names>J.</given-names></name>
<name><surname>Hodgson</surname><given-names>I.</given-names></name>
<name><surname>Le Butt</surname><given-names>C.S.</given-names></name>
<name><surname>Hill</surname><given-names>J.</given-names></name>
</person-group><article-title>Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates</article-title><source>Microb. Pathog.</source><year>2007</year><volume>42</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2006.09.003</pub-id><pub-id pub-id-type="pmid">17107769</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01361"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Agar</surname><given-names>S.L.</given-names></name>
<name><surname>Baze</surname><given-names>W.B.</given-names></name>
<name><surname>Olano</surname><given-names>J.P.</given-names></name>
<name><surname>Fadl</surname><given-names>A.A.</given-names></name>
<name><surname>Erova</surname><given-names>T.E.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Foltz</surname><given-names>S.M.</given-names></name>
<name><surname>Suarez</surname><given-names>G.</given-names></name>
<name><surname>Motin</surname><given-names>V.L.</given-names></name>
<etal/>
</person-group><article-title>Braun lipoprotein (Lpp) contributes to virulence of yersiniae: Potential role of Lpp in inducing bubonic and pneumonic plague</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>1390</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1128/IAI.01529-07</pub-id><pub-id pub-id-type="pmid">18227160</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01361"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrianaivoarimanana</surname><given-names>V.</given-names></name>
<name><surname>Randriantseheno</surname><given-names>L.N.</given-names></name>
<name><surname>Moore</surname><given-names>K.M.</given-names></name>
<name><surname>Walker</surname><given-names>N.J.</given-names></name>
<name><surname>Lonsdale</surname><given-names>S.G.</given-names></name>
<name><surname>Kempster</surname><given-names>S.</given-names></name>
<name><surname>Almond</surname><given-names>N.A.</given-names></name>
<name><surname>Rajerison</surname><given-names>M.</given-names></name>
<name><surname>Williamson</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Potential human immunotherapeutics for plague</article-title><source>Immunother. Adv.</source><year>2021</year><volume>1</volume><fpage>ltab020</fpage><pub-id pub-id-type="doi">10.1093/immadv/ltab020</pub-id><pub-id pub-id-type="pmid">35919741</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01361"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bowyer</surname><given-names>G.</given-names></name>
<name><surname>Rampling</surname><given-names>T.</given-names></name>
<name><surname>Powlson</surname><given-names>J.</given-names></name>
<name><surname>Morter</surname><given-names>R.</given-names></name>
<name><surname>Wright</surname><given-names>D.</given-names></name>
<name><surname>Hill</surname><given-names>A.V.S.</given-names></name>
<name><surname>Ewer</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Activation-induce markers detect vaccine-specific CD4+ T cell responses not measured by assays conventionally used in clinical trials</article-title><source>Vaccines</source><year>2018</year><volume>6</volume><elocation-id>50</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines6030050</pub-id><pub-id pub-id-type="pmid">30065162</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01361"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gray</surname><given-names>J.I.</given-names></name>
<name><surname>Westerhof</surname><given-names>L.M.</given-names></name>
<name><surname>MacLeod</surname><given-names>M.K.L.</given-names></name>
</person-group><article-title>The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination</article-title><source>Immunology</source><year>2018</year><volume>154</volume><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1111/imm.12929</pub-id><pub-id pub-id-type="pmid">29570776</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01361"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mills</surname><given-names>K.H.G.</given-names></name>
</person-group><article-title>IL-17 and IL-17-producing cells in protection versus pathology</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>38</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00746-9</pub-id><pub-id pub-id-type="pmid">35790881</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01361"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Moore</surname><given-names>B.B.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Xiao</surname><given-names>P.</given-names></name>
<name><surname>Decker</surname><given-names>A.M.</given-names></name>
<name><surname>Wang</surname><given-names>H.L.</given-names></name>
</person-group><article-title>IL-17: Balancing Protective Immunity and Pathogenesis</article-title><source>J. Immunol. Res.</source><year>2023</year><volume>2023</volume><fpage>3360310</fpage><pub-id pub-id-type="doi">10.1155/2023/3360310</pub-id><pub-id pub-id-type="pmid">37600066</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01361"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huangfu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>The IL-17 family in diseases: From bench to bedside</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>402</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01620-3</pub-id><pub-id pub-id-type="pmid">37816755</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01361"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Gade</surname><given-names>P.</given-names></name>
<name><surname>Kalvakolanu</surname><given-names>D.V.</given-names></name>
<name><surname>Weibley</surname><given-names>T.</given-names></name>
<name><surname>Doble</surname><given-names>B.</given-names></name>
<name><surname>Woodgett</surname><given-names>J.R.</given-names></name>
<name><surname>Wood</surname><given-names>T.D.</given-names></name>
<name><surname>Gaffen</surname><given-names>S.L.</given-names></name>
</person-group><article-title>IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain</article-title><source>Sci. Signal</source><year>2009</year><volume>2</volume><fpage>ra8</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2000066</pub-id><pub-id pub-id-type="pmid">19244213</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01361"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navarro-Comp&#x000e1;n</surname><given-names>V.</given-names></name>
<name><surname>Puig</surname><given-names>L.</given-names></name>
<name><surname>Vidal</surname><given-names>S.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>J.</given-names></name>
<name><surname>Llamas-Velasco</surname><given-names>M.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Carballido</surname><given-names>C.</given-names></name>
<name><surname>Almod&#x000f3;var</surname><given-names>R.</given-names></name>
<name><surname>Pinto</surname><given-names>J.A.</given-names></name>
<name><surname>Gal&#x000ed;ndez-Aguirregoikoa</surname><given-names>E.</given-names></name>
<name><surname>Zarco</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1191782</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1191782</pub-id><pub-id pub-id-type="pmid">37600764</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01361"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Slight</surname><given-names>S.R.</given-names></name>
<name><surname>Khader</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Th17 cytokines and vaccine-induced immunity</article-title><source>Semin. Immunopathol.</source><year>2010</year><volume>32</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s00281-009-0191-2</pub-id><pub-id pub-id-type="pmid">20112107</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01361"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khader</surname><given-names>S.A.</given-names></name>
<name><surname>Gaffen</surname><given-names>S.L.</given-names></name>
<name><surname>Kolls</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa</article-title><source>Mucosal Immunol.</source><year>2009</year><volume>2</volume><fpage>403</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/mi.2009.100</pub-id><pub-id pub-id-type="pmid">19587639</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01361"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khader</surname><given-names>S.A.</given-names></name>
<name><surname>Bell</surname><given-names>G.K.</given-names></name>
<name><surname>Pearl</surname><given-names>J.E.</given-names></name>
<name><surname>Fountain</surname><given-names>J.J.</given-names></name>
<name><surname>Rangel-Moreno</surname><given-names>J.</given-names></name>
<name><surname>Cilley</surname><given-names>G.E.</given-names></name>
<name><surname>Shen</surname><given-names>F.</given-names></name>
<name><surname>Eaton</surname><given-names>S.M.</given-names></name>
<name><surname>Gaffen</surname><given-names>S.L.</given-names></name>
<name><surname>Swain</surname><given-names>S.L.</given-names></name>
<etal/>
</person-group><article-title>IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge</article-title><source>Nat. Immunol.</source><year>2007</year><volume>8</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/ni1449</pub-id><pub-id pub-id-type="pmid">17351619</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01361"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romano</surname><given-names>M.</given-names></name>
<name><surname>D&#x02019;Souza</surname><given-names>S.</given-names></name>
<name><surname>Adnet</surname><given-names>P.Y.</given-names></name>
<name><surname>Laali</surname><given-names>R.</given-names></name>
<name><surname>Jurion</surname><given-names>F.</given-names></name>
<name><surname>Palfliet</surname><given-names>K.</given-names></name>
<name><surname>Huygen</surname><given-names>K.</given-names></name>
</person-group><article-title>Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3353</fpage><lpage>3364</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.066</pub-id><pub-id pub-id-type="pmid">16488518</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01361"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vordermeier</surname><given-names>H.M.</given-names></name>
<name><surname>Villarreal-Ramos</surname><given-names>B.</given-names></name>
<name><surname>Cockle</surname><given-names>P.J.</given-names></name>
<name><surname>McAulay</surname><given-names>M.</given-names></name>
<name><surname>Rhodes</surname><given-names>S.G.</given-names></name>
<name><surname>Thacker</surname><given-names>T.</given-names></name>
<name><surname>Gilbert</surname><given-names>S.C.</given-names></name>
<name><surname>McShane</surname><given-names>H.</given-names></name>
<name><surname>Hill</surname><given-names>A.V.</given-names></name>
<name><surname>Xing</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>3364</fpage><lpage>3373</lpage><pub-id pub-id-type="doi">10.1128/IAI.00287-09</pub-id><pub-id pub-id-type="pmid">19487476</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01361"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitsdoerffer</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>J&#x000e4;ger</surname><given-names>A.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Korn</surname><given-names>T.</given-names></name>
<name><surname>Kolls</surname><given-names>J.K.</given-names></name>
<name><surname>Cantor</surname><given-names>H.</given-names></name>
<name><surname>Bettelli</surname><given-names>E.</given-names></name>
<name><surname>Kuchroo</surname><given-names>V.K.</given-names></name>
</person-group><article-title>Proinflammatory T helper type 17 cells are effective B-cell helpers</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>14292</fpage><lpage>14297</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009234107</pub-id><pub-id pub-id-type="pmid">20660725</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01361"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baeten</surname><given-names>D.</given-names></name>
<name><surname>&#x000d8;stergaard</surname><given-names>M.</given-names></name>
<name><surname>Wei</surname><given-names>J.C.</given-names></name>
<name><surname>Sieper</surname><given-names>J.</given-names></name>
<name><surname>J&#x000e4;rvinen</surname><given-names>P.</given-names></name>
<name><surname>Tam</surname><given-names>L.S.</given-names></name>
<name><surname>Salvarani</surname><given-names>C.</given-names></name>
<name><surname>Kim</surname><given-names>T.H.</given-names></name>
<name><surname>Solinger</surname><given-names>A.</given-names></name>
<name><surname>Datsenko</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study</article-title><source>Ann. Rheum. Dis.</source><year>2018</year><volume>77</volume><fpage>1295</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2018-213328</pub-id><pub-id pub-id-type="pmid">29945918</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01361"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van der Heijde</surname><given-names>D.</given-names></name>
<name><surname>Cheng-Chung Wei</surname><given-names>J.</given-names></name>
<name><surname>Dougados</surname><given-names>M.</given-names></name>
<name><surname>Mease</surname><given-names>P.</given-names></name>
<name><surname>Deodhar</surname><given-names>A.</given-names></name>
<name><surname>Maksymowych</surname><given-names>W.P.</given-names></name>
<name><surname>Van den Bosch</surname><given-names>F.</given-names></name>
<name><surname>Sieper</surname><given-names>J.</given-names></name>
<name><surname>Tomita</surname><given-names>T.</given-names></name>
<name><surname>Landew&#x000e9;</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>2441</fpage><lpage>2451</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31946-9</pub-id><pub-id pub-id-type="pmid">30360964</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01361"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baeten</surname><given-names>D.</given-names></name>
<name><surname>Sieper</surname><given-names>J.</given-names></name>
<name><surname>Braun</surname><given-names>J.</given-names></name>
<name><surname>Baraliakos</surname><given-names>X.</given-names></name>
<name><surname>Dougados</surname><given-names>M.</given-names></name>
<name><surname>Emery</surname><given-names>P.</given-names></name>
<name><surname>Deodhar</surname><given-names>A.</given-names></name>
<name><surname>Porter</surname><given-names>B.</given-names></name>
<name><surname>Martin</surname><given-names>R.</given-names></name>
<name><surname>Andersson</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>2534</fpage><lpage>2548</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1505066</pub-id><pub-id pub-id-type="pmid">26699169</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01361"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deodhar</surname><given-names>A.</given-names></name>
<name><surname>Gensler</surname><given-names>L.S.</given-names></name>
<name><surname>Sieper</surname><given-names>J.</given-names></name>
<name><surname>Clark</surname><given-names>M.</given-names></name>
<name><surname>Calderon</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Leu</surname><given-names>J.H.</given-names></name>
<name><surname>Campbell</surname><given-names>K.</given-names></name>
<name><surname>Sweet</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis</article-title><source>Arthritis Rheumatol.</source><year>2019</year><volume>71</volume><fpage>258</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/art.40728</pub-id><pub-id pub-id-type="pmid">30225992</pub-id>
</element-citation></ref><ref id="B62-vaccines-12-01361"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chong</surname><given-names>W.P.</given-names></name>
<name><surname>Mattapallil</surname><given-names>M.J.</given-names></name>
<name><surname>Raychaudhuri</surname><given-names>K.</given-names></name>
<name><surname>Bing</surname><given-names>S.J.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Zhong</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Silver</surname><given-names>P.B.</given-names></name>
<name><surname>Jittayasothorn</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24</article-title><source>Immunity</source><year>2020</year><volume>53</volume><fpage>384</fpage><lpage>397.e385</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.022</pub-id><pub-id pub-id-type="pmid">32673565</pub-id>
</element-citation></ref><ref id="B63-vaccines-12-01361"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novatchkova</surname><given-names>M.</given-names></name>
<name><surname>Leibbrandt</surname><given-names>A.</given-names></name>
<name><surname>Werzowa</surname><given-names>J.</given-names></name>
<name><surname>Neub&#x000fc;ser</surname><given-names>A.</given-names></name>
<name><surname>Eisenhaber</surname><given-names>F.</given-names></name>
</person-group><article-title>The STIR-domain superfamily in signal transduction, development and immunity</article-title><source>Trends Biochem. Sci.</source><year>2003</year><volume>28</volume><fpage>226</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(03)00067-7</pub-id><pub-id pub-id-type="pmid">12765832</pub-id>
</element-citation></ref><ref id="B64-vaccines-12-01361"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klose</surname><given-names>C.S.</given-names></name>
<name><surname>Artis</surname><given-names>D.</given-names></name>
</person-group><article-title>Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis</article-title><source>Nat. Immunol.</source><year>2016</year><volume>17</volume><fpage>765</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1038/ni.3489</pub-id><pub-id pub-id-type="pmid">27328006</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01361"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forthal</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Functions of Antibodies</article-title><source>Microbiol. Spectr.</source><year>2014</year><volume>2</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.AID-0019-2014</pub-id><pub-id pub-id-type="pmid">26104200</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01361"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campod&#x000f3;nico</surname><given-names>V.L.</given-names></name>
<name><surname>Llosa</surname><given-names>N.J.</given-names></name>
<name><surname>Grout</surname><given-names>M.</given-names></name>
<name><surname>D&#x000f6;ring</surname><given-names>G.</given-names></name>
<name><surname>Maira-Litr&#x000e1;n</surname><given-names>T.</given-names></name>
<name><surname>Pier</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1128/IAI.00806-09</pub-id><pub-id pub-id-type="pmid">19995892</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01361"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bishop</surname><given-names>A.L.</given-names></name>
<name><surname>Schild</surname><given-names>S.</given-names></name>
<name><surname>Patimalla</surname><given-names>B.</given-names></name>
<name><surname>Klein</surname><given-names>B.</given-names></name>
<name><surname>Camilli</surname><given-names>A.</given-names></name>
</person-group><article-title>Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>4402</fpage><lpage>4420</lpage><pub-id pub-id-type="doi">10.1128/IAI.00398-10</pub-id><pub-id pub-id-type="pmid">20679439</pub-id>
</element-citation></ref><ref id="B68-vaccines-12-01361"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richards</surname><given-names>A.F.</given-names></name>
<name><surname>Baranova</surname><given-names>D.E.</given-names></name>
<name><surname>Pizzuto</surname><given-names>M.S.</given-names></name>
<name><surname>Jaconi</surname><given-names>S.</given-names></name>
<name><surname>Willsey</surname><given-names>G.G.</given-names></name>
<name><surname>Torres-Velez</surname><given-names>F.J.</given-names></name>
<name><surname>Doering</surname><given-names>J.E.</given-names></name>
<name><surname>Benigni</surname><given-names>F.</given-names></name>
<name><surname>Corti</surname><given-names>D.</given-names></name>
<name><surname>Mantis</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Recombinant Human Secretory IgA Induces Salmonella Typhimurium Agglutination and Limits Bacterial Invasion into Gut-Associated Lymphoid Tissues</article-title><source>ACS Infect. Dis.</source><year>2021</year><volume>7</volume><fpage>1221</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00842</pub-id><pub-id pub-id-type="pmid">33728898</pub-id>
</element-citation></ref><ref id="B69-vaccines-12-01361"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Zheng</surname><given-names>B.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Jiao</surname><given-names>L.</given-names></name>
<name><surname>Pan</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
</person-group><article-title>Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection</article-title><source>Microbiol. Spectr.</source><year>2024</year><volume>12</volume><elocation-id>e0105424</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.01054-24</pub-id><pub-id pub-id-type="pmid">39189763</pub-id>
</element-citation></ref><ref id="B70-vaccines-12-01361"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velappan</surname><given-names>N.</given-names></name>
<name><surname>Biryukov</surname><given-names>S.S.</given-names></name>
<name><surname>Rill</surname><given-names>N.O.</given-names></name>
<name><surname>Klimko</surname><given-names>C.P.</given-names></name>
<name><surname>Rosario-Acevedo</surname><given-names>R.</given-names></name>
<name><surname>Shoe</surname><given-names>J.L.</given-names></name>
<name><surname>Hunter</surname><given-names>M.</given-names></name>
<name><surname>Dankmeyer</surname><given-names>J.L.</given-names></name>
<name><surname>Fetterer</surname><given-names>D.P.</given-names></name>
<name><surname>Bedinger</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><elocation-id>e0305034</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0305034</pub-id><pub-id pub-id-type="pmid">38954719</pub-id>
</element-citation></ref><ref id="B71-vaccines-12-01361"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Umemura</surname><given-names>M.</given-names></name>
<name><surname>Yahagi</surname><given-names>A.</given-names></name>
<name><surname>Hamada</surname><given-names>S.</given-names></name>
<name><surname>Begum</surname><given-names>M.D.</given-names></name>
<name><surname>Watanabe</surname><given-names>H.</given-names></name>
<name><surname>Kawakami</surname><given-names>K.</given-names></name>
<name><surname>Suda</surname><given-names>T.</given-names></name>
<name><surname>Sudo</surname><given-names>K.</given-names></name>
<name><surname>Nakae</surname><given-names>S.</given-names></name>
<name><surname>Iwakura</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>3786</fpage><lpage>3796</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.6.3786</pub-id><pub-id pub-id-type="pmid">17339477</pub-id>
</element-citation></ref><ref id="B72-vaccines-12-01361"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Ritchea</surname><given-names>S.</given-names></name>
<name><surname>Logar</surname><given-names>A.</given-names></name>
<name><surname>Slight</surname><given-names>S.</given-names></name>
<name><surname>Messmer</surname><given-names>M.</given-names></name>
<name><surname>Rangel-Moreno</surname><given-names>J.</given-names></name>
<name><surname>Guglani</surname><given-names>L.</given-names></name>
<name><surname>Alcorn</surname><given-names>J.F.</given-names></name>
<name><surname>Strawbridge</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group><article-title>Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis</article-title><source>Immunity</source><year>2009</year><volume>31</volume><fpage>799</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.025</pub-id><pub-id pub-id-type="pmid">19853481</pub-id>
</element-citation></ref><ref id="B73-vaccines-12-01361"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.K.</given-names></name>
<name><surname>Mukasa</surname><given-names>R.</given-names></name>
<name><surname>Hatton</surname><given-names>R.D.</given-names></name>
<name><surname>Weaver</surname><given-names>C.T.</given-names></name>
</person-group><article-title>Developmental plasticity of Th17 and Treg cells</article-title><source>Curr. Opin. Immunol.</source><year>2009</year><volume>21</volume><fpage>274</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.05.021</pub-id><pub-id pub-id-type="pmid">19524429</pub-id>
</element-citation></ref><ref id="B74-vaccines-12-01361"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cooney</surname><given-names>L.A.</given-names></name>
<name><surname>Towery</surname><given-names>K.</given-names></name>
<name><surname>Endres</surname><given-names>J.</given-names></name>
<name><surname>Fox</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Sensitivity and resistance to regulation by IL-4 during Th17 maturation</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>4440</fpage><lpage>4450</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002860</pub-id><pub-id pub-id-type="pmid">21949021</pub-id>
</element-citation></ref><ref id="B75-vaccines-12-01361"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DiPiazza</surname><given-names>A.T.</given-names></name>
<name><surname>Leist</surname><given-names>S.R.</given-names></name>
<name><surname>Abiona</surname><given-names>O.M.</given-names></name>
<name><surname>Moliva</surname><given-names>J.I.</given-names></name>
<name><surname>Werner</surname><given-names>A.</given-names></name>
<name><surname>Minai</surname><given-names>M.</given-names></name>
<name><surname>Nagata</surname><given-names>B.M.</given-names></name>
<name><surname>Bock</surname><given-names>K.W.</given-names></name>
<name><surname>Phung</surname><given-names>E.</given-names></name>
<name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>1869</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.06.018</pub-id><pub-id pub-id-type="pmid">34270939</pub-id>
</element-citation></ref><ref id="B76-vaccines-12-01361"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gopal</surname><given-names>R.</given-names></name>
<name><surname>Monin</surname><given-names>L.</given-names></name>
<name><surname>Slight</surname><given-names>S.</given-names></name>
<name><surname>Uche</surname><given-names>U.</given-names></name>
<name><surname>Blanchard</surname><given-names>E.</given-names></name>
<name><surname>Fallert Junecko</surname><given-names>B.A.</given-names></name>
<name><surname>Ramos-Payan</surname><given-names>R.</given-names></name>
<name><surname>Stallings</surname><given-names>C.L.</given-names></name>
<name><surname>Reinhart</surname><given-names>T.A.</given-names></name>
<name><surname>Kolls</surname><given-names>J.K.</given-names></name>
<etal/>
</person-group><article-title>Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1004099</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004099</pub-id><pub-id pub-id-type="pmid">24831696</pub-id>
</element-citation></ref><ref id="B77-vaccines-12-01361"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borkner</surname><given-names>L.</given-names></name>
<name><surname>Curham</surname><given-names>L.M.</given-names></name>
<name><surname>Wilk</surname><given-names>M.M.</given-names></name>
<name><surname>Moran</surname><given-names>B.</given-names></name>
<name><surname>Mills</surname><given-names>K.H.G.</given-names></name>
</person-group><article-title>IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-F</article-title><source>Mucosal Immunol.</source><year>2021</year><volume>14</volume><fpage>1183</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1038/s41385-021-00407-5</pub-id><pub-id pub-id-type="pmid">33976385</pub-id>
</element-citation></ref><ref id="B78-vaccines-12-01361"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bowen</surname><given-names>W.</given-names></name>
<name><surname>Batra</surname><given-names>L.</given-names></name>
<name><surname>Pulsifer</surname><given-names>A.R.</given-names></name>
<name><surname>Yolcu</surname><given-names>E.S.</given-names></name>
<name><surname>Lawrenz</surname><given-names>M.B.</given-names></name>
<name><surname>Shirwan</surname><given-names>H.</given-names></name>
</person-group><article-title>Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>5708</fpage><lpage>5716</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.103</pub-id><pub-id pub-id-type="pmid">31416643</pub-id>
</element-citation></ref><ref id="B79-vaccines-12-01361"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>M.L.</given-names></name>
<name><surname>Biryukov</surname><given-names>S.S.</given-names></name>
<name><surname>Rill</surname><given-names>N.O.</given-names></name>
<name><surname>Klimko</surname><given-names>C.P.</given-names></name>
<name><surname>Hunter</surname><given-names>M.</given-names></name>
<name><surname>Dankmeyer</surname><given-names>J.L.</given-names></name>
<name><surname>Miller</surname><given-names>J.A.</given-names></name>
<name><surname>Shoe</surname><given-names>J.L.</given-names></name>
<name><surname>Mlynek</surname><given-names>K.D.</given-names></name>
<name><surname>Talyansky</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1397579</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1397579</pub-id><pub-id pub-id-type="pmid">38835755</pub-id>
</element-citation></ref><ref id="B80-vaccines-12-01361"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kilgore</surname><given-names>P.B.</given-names></name>
<name><surname>Sha</surname><given-names>J.</given-names></name>
<name><surname>Hendrix</surname><given-names>E.K.</given-names></name>
<name><surname>Neil</surname><given-names>B.H.</given-names></name>
<name><surname>Lawrence</surname><given-names>W.S.</given-names></name>
<name><surname>Peel</surname><given-names>J.E.</given-names></name>
<name><surname>Hittle</surname><given-names>L.</given-names></name>
<name><surname>Woolston</surname><given-names>J.</given-names></name>
<name><surname>Sulakvelidze</surname><given-names>A.</given-names></name>
<name><surname>Schwartz</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>A bacteriophage cocktail targeting <italic toggle="yes">Yersinia pestis</italic> provides strong post-exposure protection in a rat pneumonic plague model</article-title><source>Microbiol. Spectr.</source><year>2024</year><volume>12</volume><elocation-id>e0094224</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.00942-24</pub-id><pub-id pub-id-type="pmid">39292000</pub-id>
</element-citation></ref><ref id="B81-vaccines-12-01361"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romagnani</surname><given-names>S.</given-names></name>
<name><surname>Maggi</surname><given-names>E.</given-names></name>
<name><surname>Liotta</surname><given-names>F.</given-names></name>
<name><surname>Cosmi</surname><given-names>L.</given-names></name>
<name><surname>Annunziato</surname><given-names>F.</given-names></name>
</person-group><article-title>Properties and origin of human Th17 cells</article-title><source>Mol. Immunol.</source><year>2009</year><volume>47</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2008.12.019</pub-id><pub-id pub-id-type="pmid">19193443</pub-id>
</element-citation></ref><ref id="B82-vaccines-12-01361"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toy</surname><given-names>D.</given-names></name>
<name><surname>Kugler</surname><given-names>D.</given-names></name>
<name><surname>Wolfson</surname><given-names>M.</given-names></name>
<name><surname>Vanden Bos</surname><given-names>T.</given-names></name>
<name><surname>Gurgel</surname><given-names>J.</given-names></name>
<name><surname>Derry</surname><given-names>J.</given-names></name>
<name><surname>Tocker</surname><given-names>J.</given-names></name>
<name><surname>Peschon</surname><given-names>J.</given-names></name>
</person-group><article-title>Cutting edge: Interleukin 17 signals through a heteromeric receptor complex</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.1.36</pub-id><pub-id pub-id-type="pmid">16785495</pub-id>
</element-citation></ref><ref id="B83-vaccines-12-01361"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Annunziato</surname><given-names>F.</given-names></name>
<name><surname>Cosmi</surname><given-names>L.</given-names></name>
<name><surname>Romagnani</surname><given-names>S.</given-names></name>
</person-group><article-title>Human and murine Th17</article-title><source>Curr. Opin. HIV AIDS</source><year>2010</year><volume>5</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1097/COH.0b013e32833647c2</pub-id><pub-id pub-id-type="pmid">20543587</pub-id>
</element-citation></ref><ref id="B84-vaccines-12-01361"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Deng</surname><given-names>Z.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
</person-group><article-title>IL-17 polymorphisms and asthma risk: A meta-analysis of 11 single nucleotide polymorphisms</article-title><source>J. Asthma</source><year>2015</year><volume>52</volume><fpage>981</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.3109/02770903.2015.1044251</pub-id><pub-id pub-id-type="pmid">26300019</pub-id>
</element-citation></ref><ref id="B85-vaccines-12-01361"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>Y.M.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
</person-group><article-title>Interleukin-17 gene polymorphisms contribute to cancer risk</article-title><source>Mediat. Inflamm.</source><year>2014</year><volume>2014</volume><fpage>128490</fpage><pub-id pub-id-type="doi">10.1155/2014/128490</pub-id><pub-id pub-id-type="pmid">25147431</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01361-f001"><label>Figure 1</label><caption><p>Vaccination protected both IL-17A-depleted and IgG control mice against lethal pulmonary <italic toggle="yes">Y. pestis</italic> challenge. (<bold>A</bold>) Experimental time course. Swiss Webster mice (<italic toggle="yes">n =</italic> 10 per group) administered anti-IL-17A or its IgG isotype control mAbs twice per week were immunized with either LMA or LMP alone by i.m. injection or in combination with i.n. instillation of Ad5-YFV in a 2-dose regimen, 21 days apart. Mice receiving PBS were used as challenge controls. (<bold>B</bold>,<bold>C</bold>) Approximately 3 weeks after the completion of the vaccination schedule, mice were i.n. challenged with 100 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92. (<bold>D</bold>,<bold>E</bold>) Seven days post-initial challenge, survivors among vaccinated mice, along with age-matched na&#x000ef;ve control mice, were re-challenged i.n. with 10,000 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92 and observed for morbidity and mortality for 21 days. Kaplan&#x02013;Meier analysis with log-rank (Mantel&#x02013;Cox) test was used to analyze survival. Asterisks represent the statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vaccines-12-01361-g001" position="float"/></fig><fig position="float" id="vaccines-12-01361-f002"><label>Figure 2</label><caption><p>Serum IgG titers and their sub-isotypes to the F1V fusion protein in vaccinated IL-17A-depleted and IgG control mice. Boost sera were collected on day 37 as described in <xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A and ELISAs were performed to evaluate (<bold>A</bold>) total IgG and (<bold>B</bold>,<bold>C</bold>) IgG isotype titers to F1V. Significance was determined by either one-way ANOVA with Tukey&#x02019;s post hoc test (<bold>A</bold>) or two-way ANOVA with Tukey&#x02019;s post hoc test (<bold>B</bold>,<bold>C</bold>). The geometric means &#x000b1; standard deviations are plotted. The blue dashed line represents the baseline values of na&#x000ef;ve control samples at the dilution of 1:500. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. *, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001. These data were combined from three independent ELISA assays.</p></caption><graphic xlink:href="vaccines-12-01361-g002" position="float"/></fig><fig position="float" id="vaccines-12-01361-f003"><label>Figure 3</label><caption><p>Serum IgG antibody responses to specific individual plague antigens in vaccinated IL-17A-depleted and IgG control mice. Boost sera were collected on day 37 as described in <xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A and ELISAs were performed to evaluate IgG titers to individual plague antigens (<bold>A</bold>) F1, (<bold>B</bold>) LcrV, and (<bold>C</bold>) YscF. The geometric means &#x000b1; standard deviations are plotted. Statistical significance was determined by one-way ANOVA with Tukey&#x02019;s post hoc test. The blue dashed line represents the baseline values of na&#x000ef;ve control samples at the dilution of 1:500. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001. These data are combined from three independent ELISA assays.</p></caption><graphic xlink:href="vaccines-12-01361-g003" position="float"/></fig><fig position="float" id="vaccines-12-01361-f004"><label>Figure 4</label><caption><p>Neutralizing antibodies in vaccinated IL-17A-depleted mice. Animals were immunized and serum was collected as described in <xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A. Competitive ELISAs were performed using biotinylated neutralizing and protective LcrV Mab7.3 against serum from animals vaccinated with (<bold>A</bold>) Ad5-YFV&#x02013;LMA, (<bold>B</bold>) Ad5-YFV&#x02013;LMP, (<bold>C</bold>) LMA&#x02013;Ad5-YFV, or (<bold>D</bold>) LMP&#x02013;Ad5-YFV in binding of rV. The percentage inhibition of biotinylated LcrV Mab7.3 binding to rV by immunized sera was plotted. The blue dashed line represents 50% of the biotinylated LcrV Mab7.3 outcompeted for binding. The area to the left of the vertical solid line depicts the competitive binding capacity of sera at 2-fold increasing dilutions. The area to the right of the vertical solid line depicts the comparison of competitive binding ability of serum at a 1:80 dilution with biotinylated LcrV Mab7.3 between IL-17A-depleted (striped blue bar) and IgG control (solid blue bar) groups. Averages from representative experiments are plotted.</p></caption><graphic xlink:href="vaccines-12-01361-g004" position="float"/></fig><fig position="float" id="vaccines-12-01361-f005"><label>Figure 5</label><caption><p>BALF IgA titers in vaccinated IL-17A-depleted and IgG control mice. Animals were immunized and BALF was collected as described in <xref rid="vaccines-12-01361-f001" ref-type="fig">Figure 1</xref>A. IgA ELISAs were performed to evaluate titers to (<bold>A</bold>) F1V fusion plague antigen and individual plague antigens (<bold>B</bold>) F1, (<bold>C</bold>) LcrV, and (<bold>D</bold>) YscF. The geometric means &#x000b1; standard deviations are plotted. Statistical significance was determined by one-way ANOVA with Tukey&#x02019;s post hoc test. The blue dashed line represents the baseline values of na&#x000ef;ve control samples at the dilution of 1:500. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001. These data are combined from three independent ELISA assays.</p></caption><graphic xlink:href="vaccines-12-01361-g005" position="float"/></fig><fig position="float" id="vaccines-12-01361-f006"><label>Figure 6</label><caption><p>Germinal center B cell activities and memory B cell populations in vaccinated IL-17A depleted and IgG control mice. Spleens were collected 4 weeks post-boost immunization from vaccinated and na&#x000ef;ve control mice (<italic toggle="yes">n</italic> = 5 per group). (<bold>A</bold>) Splenocytes were surface-stained with various B cell markers and subjected to flow cytometry. The percentage of B cells in (<bold>B</bold>) germinal centers was gated as CD3<sup>-</sup>CD138<sup>-</sup>CD19<sup>+</sup>CD38<sup>-</sup>GL7<sup>+</sup>, while (<bold>C</bold>) memory B cells were identified as CD3<sup>-</sup>CD138<sup>-</sup>CD19<sup>+</sup>CD38<sup>+</sup>GL7<sup>-</sup>IgD<sup>-</sup>. The arithmetic means &#x000b1; standard deviations are plotted. Statistical significance was determined using one-way ANOVA with Tukey&#x02019;s post hoc test. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent the statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. *, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vaccines-12-01361-g006" position="float"/></fig><fig position="float" id="vaccines-12-01361-f007"><label>Figure 7</label><caption><p>Cytokine-positive T cells in vaccinated IL-17A-depleted and IgG control mice. Spleens were collected 4 weeks post-boost immunization from vaccinated and na&#x000ef;ve control mice (<italic toggle="yes">n =</italic> 5 per group). The isolated splenocytes were stimulated with rF1V (100 &#x000b5;g/mL) for 48 h at 37&#x000b0;C, followed by an additional 4 h with Brefeldin A. Splenocytes were surface- and intracellularly stained with various cytokine and T cell markers and subjected to flow cytometry. (<bold>A</bold>,<bold>C</bold>,<bold>E</bold>,<bold>G</bold>,<bold>I</bold>). The percentages of cytokine-positive CD4<sup>+</sup> and (<bold>B</bold>,<bold>D</bold>,<bold>F,H</bold>,<bold>J</bold>) CD8<sup>+</sup> populations were acquired. The arithmetic means &#x000b1; standard deviations are plotted. Statistical significance was determined using one-way ANOVA with Tukey&#x02019;s post hoc test. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent the statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vaccines-12-01361-g007" position="float"/></fig><fig position="float" id="vaccines-12-01361-f008"><label>Figure 8</label><caption><p>Evaluation of T cell response through the activation-induced marker (AIM) assay. Spleens were collected 4 weeks post-boost immunization from vaccinated and na&#x000ef;ve control mice (<italic toggle="yes">n =</italic> 5 per group). The isolated splenocytes were stimulated with rF1V (100 &#x000b5;g/mL) for 48 h at 37 &#x000b0;C, followed by an additional 4 h with Brefeldin A. T cells were then harvested and stained with specific T cell AIM markers for flow cytometry analysis. The percentages of positive AIM populations in (<bold>A</bold>) CD4<sup>+</sup>CD44<sup>+</sup>CD134<sup>+</sup>CD25<sup>+</sup> and (<bold>B</bold>) CD8<sup>+</sup>CD44<sup>+</sup>CD69<sup>+</sup>CD25<sup>+</sup> were acquired. The arithmetic means &#x000b1; standard deviations are plotted. Statistical significance was determined using one-way ANOVA with Tukey&#x02019;s post hoc test. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent the statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vaccines-12-01361-g008" position="float"/></fig><fig position="float" id="vaccines-12-01361-f009"><label>Figure 9</label><caption><p>Memory T cell populations in vaccinated IL-17A-depleted and IgG control mice. Spleens were collected 4 weeks post-boost immunization from vaccinated and na&#x000ef;ve control mice (<italic toggle="yes">n =</italic> 5 per group). The isolated splenocytes were stimulated with rF1V (100 &#x000b5;g/mL) for 48 h at 37 &#x000b0;C, followed by an additional 4 h with Brefeldin A. Cells were then harvested and stained with various T cell markers and subjected to flow cytometry. (<bold>A</bold>) Central memory T cells (TCM) were identified as CD44<sup>+</sup>CD127<sup>+</sup>CD62L<sup>+</sup>, while (<bold>B</bold>) effector memory T cells (TEM) were identified as CD44<sup>+</sup>CD127<sup>+</sup>CD62L<sup>-</sup>. The arithmetic means &#x000b1; standard deviations are plotted. Statistical significance was determined using one-way ANOVA with Tukey&#x02019;s post hoc test. Asterisks with comparison bars represent statistical significance between respective vaccinated groups, while asterisks directly above the bars represent the statistical significance of vaccinated groups compared to na&#x000ef;ve control mice. * <italic toggle="yes">p</italic> &#x0003c; 0.05; ** <italic toggle="yes">p</italic> &#x0003c; 0.01; *** <italic toggle="yes">p</italic> &#x0003c; 0.001; **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="vaccines-12-01361-g009" position="float"/></fig></floats-group></article>